<SEC-DOCUMENT>0001437749-19-022543.txt : 20191113
<SEC-HEADER>0001437749-19-022543.hdr.sgml : 20191113
<ACCEPTANCE-DATETIME>20191112185050
ACCESSION NUMBER:		0001437749-19-022543
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20191113
DATE AS OF CHANGE:		20191112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Diffusion Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-234234
		FILM NUMBER:		191211291

	BUSINESS ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		(434) 220-0718

	MAIL ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.
		DATE OF NAME CHANGE:	20080228
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>dffn20191112_s1a.htm
<DESCRIPTION>FORM S-1/A
<TEXT>
<html><head>
	<title>dffn20191014_s1.htm</title>

	<!-- Generated by ThunderDome Portal - 11/12/2019 11:38:55 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 3pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 3pt;text-align:center;"> As filed with the Securities and Exchange Commission on November 12, 2019 </p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 3pt;text-align:center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 3pt; text-align: right;"><b>Registration No. 333-234234&nbsp; </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;"><b>UNITED STATES<br>
SECURITIES AND EXCHANGE COMMISSION</b><br>
<b>Washington, D.C. 20549 </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;"> <b>Amendment no. 3&nbsp;to</b> </p>

<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;"><b>FORM S-1</b><br>
<b>REGISTRATION STATEMENT</b><br>
<b><i>UNDER THE SECURITIES ACT OF 1933</i></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:18pt;margin:0pt;text-align:center;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(Exact name of registrant as specified in its charter)</b>&nbsp;<br>
&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:99.8%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:bottom;width:33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Delaware</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 31%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>2834</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>30-0645032</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(State or other jurisdiction of<br>
			incorporation or organization)</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 31%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(Primary Standard Industrial<br>
			Classification Code Number)</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(I.R.S. Employer<br>
			Identification Number)</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>1317 Carlton Avenue, Suite </b><b>2</b><b>00<br>
Charlottesville, VA 22902<br>
(434) 220-0718 </b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices) </b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>David G. Kalergis<br>
Chief Executive Officer<br>
1317 Carlton Avenue, Suite </b><b>2</b><b>00<br>
Charlottesville, VA 22902<br>
(434) 220-0718</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(Name, address, including zip code, and telephone number, including area code, of agent for service) </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">With a Copy to:</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>David S. Rosenthal, Esq.<br>
			Dechert LLP<br>
			1095 Avenue of the Americas<br>
			New York, New York 10036<br>
			(212) 698-3500</b></p>
			</td>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Robert F. Charron, Esq.</b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Ellenoff Grossman&nbsp;&amp; Schole LLP</b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>1345 Avenue of the Americas</b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>New York, New York 10105</b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(212) 370-1300</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Approximate date of commencement of proposed sale to the public:</b> As soon as practicable after the effective date of this registration statement.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), check the following box. &#9746;&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 60%;">&nbsp;Large accelerated filer &#9744;</td>
			<td style="width: 40%;">Accelerated filer &#9744;</td>
		</tr>
		<tr>
			<td style="width: 60%;">&nbsp;Non-accelerated filer &#9746;</td>
			<td style="width: 40%;">Smaller reporting company &#9746;</td>
		</tr>
		<tr>
			<td style="width: 60%;">&nbsp;</td>
			<td style="width: 40%;">Emerging growth company &#9744;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:2pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act.&#9744;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>CALCULATION OF REGISTRATION FEE </b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Title of each class of securities to be registered</b></p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>Proposed maximum<br>
			aggregate offering<br>
			price(1)</b></b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>Amount of<br>
			registration fee</b></b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="width: 68%;">&nbsp;</td>
			<td id=".lead.B2" style="width: 1%;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%;">&nbsp;</td>
			<td id=".amt.B2" style="width: 12%;">&nbsp;</td>
			<td id=".trail.B2" style="width: 2%;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%;">&nbsp;</td>
			<td id=".amt.B3" style="width: 12%;">&nbsp;</td>
			<td id=".trail.B3" style="width: 2%;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Class A Units consisting of: (2)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,000,000</td>
			<td id=".trail.2" nowrap="true" style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,038.40</td>
			<td id=".trail.3" nowrap="true" style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 36pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">(i) Common Stock, par value $0.001 per share</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 36pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">(ii) Series I Warrants to purchase shares of Common Stock (4)</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 36pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">(iii) Series II Warrants to purchase shares of Common Stock (4)</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Class B Units consisting of: (2)</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 36pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">(i) Pre-funded warrants to purchase shares of Common Stock (4)</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 36pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">(ii) Series I Warrants to purchase shares of Common Stock (4)</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 36pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">(iii) Series II Warrants to purchase shares of Common Stock (4)</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common Stock issuable upon exercise of Pre-funded Warrants (4)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.2" nowrap="true" style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.3" nowrap="true" style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common Stock issuable upon exercise of Series I Warrants (4)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,000,000</td>
			<td id=".trail.2" nowrap="true" style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,038.40</td>
			<td id=".trail.3" nowrap="true" style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common Stock issuable upon exercise of Series II Warrants (4)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,000,000</td>
			<td id=".trail.2" nowrap="true" style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,038.40</td>
			<td id=".trail.3" nowrap="true" style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Placement Agent&#8217;s Warrant to purchase shares of Common Stock and common stock issuable upon exercise thereof (3)(4)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">500,000</td>
			<td id=".trail.2" nowrap="true" style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">64.90</td>
			<td id=".trail.3" nowrap="true" style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Total</b></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24,500,000</td>
			<td id=".trail.2" nowrap="true" style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;(5)&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,180.10</td>
			<td id=".trail.3" nowrap="true" style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp; (6)</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:4.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">(1)</p>
			</td>
			<td style="vertical-align:top;width:95.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Estimated solely for the purpose of calculating the amount of the registration fee in accordance with Rule 457(o) under the Securities Act.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:4.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">(2)</p>
			</td>
			<td style="vertical-align:top;width:95.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The proposed maximum aggregate offering price of the Class&nbsp;A Units will be reduced on a&nbsp;dollar-for-dollar&nbsp;basis based on the offering price of any Class&nbsp;B Units offered and sold in the offering (plus the aggregate exercise price of the common stock issuable upon exercise of the pre-funded warrants sold as a part of the Class B Units), and the proposed maximum aggregate offering price of the Class&nbsp;B Units to be sold in the offering will be reduced on a&nbsp;dollar-for-dollar&nbsp;basis based on the offering price of any Class&nbsp;A Units sold in the offering such that the proposed aggregate maximum offering price of the Class A Units and Class B Units (plus the aggregate exercise price of the common stock issuable upon exercise of the pre-funded warrants sold as a part of the Class B Units) will be $8,000,000.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:4.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">(3)</p>
			</td>
			<td style="vertical-align:top;width:95.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Represents warrants issuable to H.C. Wainwright &amp; Co., LLC (the &#8220;Placement Agent&#8217;s Warrants&#8221;) to purchase a number of shares of common stock equal to 5% of the number of Class A Units and Class B Units being offered at an exercise price equal to 125% of the public offering price of the Class A Unit. See &#8220;Underwriting.&#8221;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:4.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">(4)</p>
			</td>
			<td style="vertical-align:top;width:95.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Resales of the Series I Warrants, Series II Warrants and the pre-funded warrants sold as a part of the Class A Units and/or the Class B Units and the Placement Agent&#8217;s Warrants on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended, are registered hereby. Resales of shares of common stock issuable upon exercise of the Placement Agent&#8217;s Warrants, the pre-funded warrants, the Series I Warrants and the Series II Warrants are also being registered on a delayed or continuous basis hereby.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:4.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">(5)</p>
			</td>
			<td style="vertical-align:top;width:95.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Pursuant to Rule 416 under the Securities Act, the securities being registered hereunder include such indeterminate number of additional securities as may be issued after the date hereof as a result of stock splits, stock dividends or similar transactions.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> (6) </p>
			</td>
			<td style="vertical-align:top;width:95.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> Previously paid. </p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><font style="color:#ff0000;">The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> <font style="color:#ff0000;">Subject to completion, dated November 12, 2019</font> </p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>PRELIMINARY PROSPECTUS</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div style="text-align: center;"><img alt="" src="image01.jpg"></div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>Up to $8,000,000 consisting of</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>12,121,212&nbsp;Class A Units consisting of Shares of Common Stock and Series I Warrants and Series II Warrants or</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>12,121,212&nbsp;Class B Units consisting of Pre-Funded Warrants and Series I Warrants and Series II Warrants</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>(or some combination of Class A Units and Class B Units)</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>12,121,212&nbsp;Shares of Common Stock underlying the Series I Warrants</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>12,121,212&nbsp;Shares of Common Stock underlying the Series II Warrants</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> We are offering&nbsp;12,121,212 Class A Units with each Class A Unit at a public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per Class A Unit consisting of one share of our common stock, one Series I Warrant to purchase one share of our common stock and one Series II Warrant to purchase one share of our common stock. The Class&nbsp;A Units will not be certificated and the share of common stock, the Series I Warrant and Series II Warrant comprising such unit are immediately separable and will be issued separately in this offering. </p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We are also offering to certain purchasers whose purchase of Class&nbsp;A Units in this offering would result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock following the consummation of this offering, the opportunity to purchase, in lieu of Class&nbsp;A Units that would result in ownership in excess of 4.99% (or, at the election of the purchaser, 9.99%) or otherwise at such purchaser&#8217;s election, Class&nbsp;B Units, with each Class&nbsp;B Unit consisting of&nbsp;one&nbsp;pre-funded&nbsp;warrant to purchase one share of our common stock, or a&nbsp;pre-funded&nbsp;warrant, one Series I Warrant to purchase one share of our common stock and one Series II Warrant to purchase one share of our common stock. The purchase price of each Class B Unit will be equal to the price at which a Class A Unit is sold to the public in this offering, minus $0.001, and the exercise price of each pre-funded warrant will be $0.001 per share.&nbsp; The Class&nbsp;B Units will not be certificated and the&nbsp;pre-funded&nbsp;warrant, the Series I Warrant and Series II Warrant comprising such unit are immediately separable and will be issued separately in this offering. Each purchase of Class&nbsp;B Units in this offering will reduce the number of Class&nbsp;A Units in this offering on a one-for-one basis. Therefore the number of Series I Warrants and Series II Warrants sold in this offering will not change as a result of a change in the mix of the Class A Units sold and Class B Units Sold.&nbsp;The pre-funded warrants will be immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full.&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> Each Series I Warrant will have an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock, will be exercisable upon issuance and will expire&nbsp;eighteen months from the date of issuance. Each Series II Warrant will have an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock, will be exercisable upon issuance and will expire&nbsp;five years from the date of issuance. </p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> This offering is being conducted on a best efforts basis. There is no minimum number of Class A Units or Class B Units or minimum aggregate amount of proceeds for this offering to close. The offering of the Class A Units and the Class B Units will terminate on the first date that we enter into securities purchase agreements to sell Class A Units and Class B Units pursuant to this prospectus. </p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;DFFN.&#8221;&nbsp;&nbsp; On November 7, 2019, the reported closing price per share of our common stock was $0.66. Assuming we sell all $8,000,000 of Class&nbsp;A Units (and no Class&nbsp;B Units) being offered in this offering at an assumed public offering price of $0.66 per Class&nbsp;A Unit, the reported closing price of our common stock on the Nasdaq Capital Market on November 7, 2019, we would issue in this offering an aggregate of&nbsp;12,121,212 shares of our common stock, Series I Warrants to purchase up to&nbsp;12,121,212 shares of our common stock and Series II Warrants to purchase up to&nbsp;12,121,212 shares of our common stock.&nbsp;The public offering price per Class A Unit or Class B Unit will be determined at the time of pricing, and may be at a discount to the then current market price of our common stock. There is no established public trading market for the pre-funded warrants, the Series I Warrants, the Series II Warrants and the Placement Agent&#8217;s Warrants and we do not expect a market to develop. Without an active trading market, the liquidity of the warrants will be limited. In addition, we do not intend to list the pre-funded warrants, the Series I Warrants, the Series II Warrants or the Placement Agent&#8217;s Warrants on the Nasdaq Capital Market, any other national securities exchange or any other trading system. </p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Investing in our securities involves a high degree of risk. See the section entitled &#8220;Risk Factors&#8221; beginning on page 7</b><b>&nbsp;of this prospectus and in the documents incorporated by reference into this prospectus for a discussion of risks that should be considered in connection with an investment in our securities.</b>&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</b>&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Per Class A Unit (one share of common stock, one Series I Warrant and one Series II Warrant)</b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Per Class B Unit&nbsp;</b><b>(one Pre-funded Warrant, one Series I Warrant and one Series II Warrant)</b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Total</b></b></p>
			</td>
			<td id=".trail.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Public offering price</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Placement Agent&#8217;s fees (1)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Proceeds, before expenses, to us (2)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;&nbsp;</p>

<hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0">
<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:4.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">(1)</p>
			</td>
			<td style="vertical-align:top;width:95.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We have agreed to reimburse the placement agent for certain of its expenses. In addition, we have agreed to issue to the Placement Agent warrants to purchase&nbsp;up to&nbsp;a number of shares of our common stock equal to 5% of the number of Class A Units and Class B Units sold in this offering. See &#8220;Plan of Distribution&#8221; for additional information and a description of the compensation payable to the Placement Agent.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:4.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">(2)</p>
			</td>
			<td style="vertical-align:top;width:95.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We estimate the total expenses of this offering payable by us, excluding the Placement Agent&#8217;s fees, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p>&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We engaged H.C. Wainwright &amp; Co., LLC as our exclusive Placement Agent to use its reasonable best efforts to solicit offers to purchase the Class A Units and Class B Units in this offering. The Placement Agent has no obligation to buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities. The securities are expected to be delivered to purchasers on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;"><b>H.C. Wainwright &amp; Co.</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">The date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>TABLE OF CONTENTS</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: bottom; width: 95%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>
			</td>
			<td colspan="2" style="vertical-align: bottom; width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;"><b>Page&nbsp;</b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">About this Prospectus</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">ii</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 95%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Prospectus Summary</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">1</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Offering</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">5</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 95%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Risk Factors</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">7</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Special Note Regarding Forward-Looking Statements</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">11</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 95%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Use of Proceeds</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">13</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Capitalization</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">14</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 95%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Description of Capital Stock</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">15</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Plan of Distribution</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">21</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 95%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Material U.S. Federal Income Tax Considerations</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">25</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Legal Matters</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">31</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 95%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Experts</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">31</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Where You Can Find Additional Information</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">31</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 95%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporation of Certain Information by Reference</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">31</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>ABOUT THIS PROSPECTUS</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">You should rely only on the information contained or incorporated by reference in this prospectus. We have not authorized anyone to provide you with information different from that contained in this prospectus.&nbsp;You should not assume that the information in this prospectus is accurate at any date other than the date indicated on the cover page of this prospectus or the filing date of any document incorporated by reference, regardless of its time of delivery. We are offering to sell Class A Units and Class B Units and seeking offers to buy Class A Units and Class B Units only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of the Class A Units and Class B Units.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">For investors outside the United States: neither we nor the Placement Agent have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the Class A Units and Class B Units and the distribution of this prospectus outside the United States.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ii</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:0.75pt;margin-top:0pt;text-align:center;"><b>PROSPECTUS SUMMARY</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 0.75pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 0.75pt;text-align:justify;"><i>This summary highlights information contained in other parts of this prospectus or incorporated by reference into this prospectus from our filings with the Securities and Exchange Commission (the &#8220;SEC&#8221;). As it is only a summary, it does not contain all of the information that you should consider before purchasing our securities in this offering and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere or incorporated by reference into this prospectus. You should read the entire prospectus, the registration statement of which this prospectus is a part, and the information incorporated by reference herein in their entirety, including the &#8220;Risk Factors&#8221; and our financial statements and the related notes contained in and incorporated by reference into this prospectus, before purchasing our securities in this offering. Unless otherwise mentioned or unless the context requires otherwise, all references in this prospectus to &#8220;Diffusion,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; or similar references mean Diffusion Pharmaceuticals Inc.</i></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Diffusion Pharmaceuticals Inc.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Business Overview</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">We are a clinical stage biotechnology company developing new treatments for life-threatening conditions by improving the body&#8217;s ability to bring oxygen to the areas where it is needed most. We are developing our lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (&#8220;TSC&#8221;), for use in those life-threatening conditions in which cellular oxygen deprivation (&#8220;hypoxia&#8221;) is the basis for significant unmet medical needs. TSC is designed to safely and selectively target and re-oxygenate the micro-environment of hypoxic cells, and can potentially be used in many indications, including stroke, oncology and cardiovascular disease. In stroke, TSC helps promote the diffusion of oxygen into those brain cells in which oxygen-deprivation causes neuronal death resulting in patient mortality or morbidity. In cancer, TSC re-oxygenates treatment-resistant cancerous tissue, making the cancer cells up to three times more susceptible to the therapeutic effects of standard-of-care radiation therapy and chemotherapy.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">A range of tissue types, including both normal and cancerous cells, has been shown to be safely re-oxygenated in our preclinical and clinical studies using TSC&#8217;s novel mechanism of action. We believe TSC&#8217;s ability to re-oxygenate normal tissue that has become oxygen-deprived provides opportunities for new therapeutic approaches to conditions ranging from stroke and emergency medicine to cardiovascular and neurodegenerative diseases. In oncology, we believe TSC&#8217;s therapeutic potential is not limited to one specific tumor type, thereby making it potentially useful to improve standard-of-care treatments in many life-threatening cancers. Given TSC's safety profile and animal data, we could, with appropriate funding, move directly into Phase 2 studies for TSC in many such cancers. The successful completion of trials for TSC or any other potential product candidate in these or any other indication is dependent upon our ability to further raise necessary capital.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">We believe that TSC has potential applications in stroke and emergency medicine. A Phase 2 trial in cooperation with UCLA and the University of Virginia to test TSC in the treatment of acute stroke has received approval for enrollment by the FDA. We enrolled our first patient in the study in October 2019. This trial, which will feature in-ambulance dosing of TSC, is named the PreHospital Acute Stroke Therapy - TSC (PHAST - TSC) and is expected to enroll 160 patients, with 80 in the treatment arm and 80 in the control arm. We believe in-ambulance dosing of TSC could significantly cut the time in which the stroke-related oxygen deprivation to brain cells goes untreated, potentially leading to a better outcome for stroke victims treated in this manner. Subject to receipt of adequate funding to support the PHAST &#8211; TSC trial, we expect to receive data readout during the first half of 2021.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Our primary oncology program targets TSC against treatment-resistant brain cancer. A Phase 2 clinical program, completed in the second quarter of 2015, evaluated 59 patients with newly diagnosed glioblastoma multiforme (&#8220;GBM&#8221;), a particularly deadly form of primary brain cancer. GBM affects approximately 12,000 patients annually in the United States and approximately 35,000 patients annually worldwide. This open label, historically controlled study demonstrated a favorable safety and efficacy profile for TSC when combined with GBM&#8217;s standard of care, including a 37% improvement in overall survival over the control group at two years. A particularly strong efficacy signal was seen in the inoperable patients, where survival of TSC-treated patients at two years was increased by almost four-fold over the controls. In December 2017, the Company initiated the INvestigation of TSC Against Cancerous Tumors (INTACT) Phase 3 trial in the newly diagnosed inoperable GBM patient population. The trial is designed to enroll 236 patients in total, with 118 in the treatment arm and 118 in the control arm.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">1</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The trial began with an open label 8 patient safety run-in for which enrollment has completed and is now closed. With the FDA&#8217;s permission, a total of 19 patients were enrolled to ensure 8 complete data sets. The INTACT Trial Data Safety Monitoring Board (DSMB) met in the third quarter of 2019 and recommended that the study be continued. The DSMB concluded that no adverse safety signal had been observed, and unanimously recommended continuing the study as planned using the highest tested dose of TSC &#8211; 1.5 mg/kg &#8211; during the adjuvant treatment chemotherapy period with temozolomide. Commencement of enrollment in the randomization portion of the INTACT Phase 3 Trial is contingent upon our entering into a strategic partnership providing the necessary resources to undertake the full trial.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">In addition to the TSC programs, we are exploring alternatives regarding how best to capitalize upon our product candidate RES-529, which may include possible out-licensing and other options. RES-529 is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase 1 clinical trials for age-related macular degeneration and was in preclinical development in oncology. RES-529 has shown activity in both in vitro and in vivo glioblastoma animal models and has been demonstrated to be orally bioavailable and capable of crossing the blood-brain barrier.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Summary of Current Product Candidate Pipeline</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 18pt;">The following table, as of September&nbsp;30, 2019, summarizes the targeted primary indications for Diffusion&#8217;s lead molecule, TSC, and RES-529:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;<img src="dffn20191014_s1img002.jpg" style="width: 445pt; height: 252pt;"></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>TSC Stroke Program</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;">We believe that TSC has potential application as a treatment for stroke. Approximately 800,000 strokes occur in the United States each year, with an estimated annual cost of $43.0 billion. The damage from a stroke begins immediately upon onset: brain cell death begins immediately at the onset of a stroke. A stroke can take a significant toll on its victims. Among long-term stroke survivors, approximately 66% of stroke patients end up needing mental or physical rehabilitation, approximately 40% are classified as moderately to severely disabled after the initial few days of recovery, and approximately 10% of stroke patients require long-term care.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;">We believe in-ambulance dosing of TSC could significantly cut the time in which the stroke-related oxygen deprivation to brain cells goes untreated, potentially leading to a better outcome for stroke victims treated in this manner. Half of all stroke patients are transported to hospitals by emergency medical services (EMS), such as ambulances, with estimates of up to 80% of all patients in urban and suburban areas being transported by EMS.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;">TSC has shown pre-clinical efficacy as a potential treatment for ischemic and hemorrhagic stroke in laboratory testing. Rabbits receiving TSC alone at one hour after developing a clot have shown a statistically significant positive response to treatment. Additionally, rabbits receiving TSC in conjunction with Tissue Plasminogen Activator (tPA) at three hours after developing a clot have shown a statistically significant positive response to treatment. Additionally, rats dosed with TSC in a hemorrhagic stroke showed a statistically significant decrease in damaged brain cells. The following charts provide additional detail on these animal studies:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt; text-align: center;"><img src="dffn20191014_s1img003.gif" style="width: 428pt; height: 240pt;"></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt; text-align: center;"><img src="dffn20191014_s1img004.gif" style="width: 428pt; height: 240pt;"></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">3</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Corporate Information</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;">We are a Delaware corporation that was incorporated in June 2015. Prior to June 2015, we were a Nevada corporation. We maintain our principal executive offices at 1317 Carlton Avenue, Suite 200, Charlottesville, VA 22902. Our telephone number there is (434) 220-0718. The address of our website is&nbsp;<i>www.diffusionpharma.com</i>. The information set forth on, or connected to, our website is expressly not incorporated by reference into, and does not constitute a part of, this prospectus.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;">We are a &#8220;smaller reporting company&#8221; as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and have elected to take advantage of certain of the scaled disclosure available for smaller reporting companies in this prospectus as well as our filings under the Exchange Act.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 0.75pt;text-align:center;"><b>THE OFFERING</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 0.75pt;text-align:center;"><b>&nbsp;</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width: 45%; vertical-align: top;">Class A Units offered by us in this offering</td>
			<td style="vertical-align: top; width: 55%; text-align: justify;">
			<p style="margin: 0pt;">We are offering up to $8,000,000 of Class&nbsp;A Units and Class&nbsp;B Units. Each Class&nbsp;A Unit consists of one share of our common stock, one Series I Warrant to purchase one share of our common stock and one Series II Warrant to purchase one share of our common stock. The Class&nbsp;A Units will not be certificated and the shares of common stock, Series I Warrants and Series II Warrants comprising such unit are immediately separable and will be issued separately in this offering.</p>

			<p style="margin: 0pt;">&nbsp;</p>

			<p style="margin: 0pt;">This prospectus also relates to the offering of shares of our common stock issuable upon the exercise of the warrants included in the Class&nbsp;A Units.</p>

			<p style="margin: 0pt;">&nbsp;</p>

			<p style="margin: 0pt;">Assuming we sell all $8,000,000&nbsp;of Class&nbsp;A Units (and no Class&nbsp;B Units) being offered in this offering at an assumed public offering price of $0.66&nbsp;per Class&nbsp;A Unit, the last reported closing price of our common stock on the Nasdaq Capital Market on November 7, 2019, we would issue in this offering an aggregate of&nbsp;12,121,212 shares of our common stock, Series I Warrants to purchase up to&nbsp;12,121,212 shares of our common stock and Series II Warrants to purchase up to&nbsp;12,121,212 shares of our common stock. There is no minimum number of Class&nbsp;A Units or Class&nbsp;B Units or aggregate amount of proceeds for this offering to close.</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 55%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 45%; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Class B Units offered by us in this offering</p>
			</td>
			<td style="vertical-align: top; width: 55%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: justify; font-size: 10pt;">We are also offering to those purchasers, whose purchase of Class&nbsp;A Units in this offering would result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock following the consummation of this offering, the opportunity to purchase, in lieu of Class&nbsp;B Units that would result in ownership in excess of 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock following the consummation of this offering or otherwise at such purchaser&#8217;s election, Class&nbsp;B Units. Each Class&nbsp;B Unit consists of one&nbsp;pre-funded&nbsp;warrant to purchase one share of our common stock, or a&nbsp;pre-funded&nbsp;warrant, one Series I Warrant to purchase one share of our common stock and one Series II Warrant to purchase one share of our common stock. The purchase price for each Class&nbsp;B warrant would equal the per unit public offering price for the Class&nbsp;A Units in this offering less the $0.001&nbsp;per share exercise price of the&nbsp;pre-funded&nbsp;warrant part of the Class&nbsp;B Unit, and the exercise price of each&nbsp;pre-funded&nbsp;warrant would equal $0.001&nbsp;per share.</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: justify; font-size: 10pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: justify; font-size: 10pt;">The Class&nbsp;B Units will not be certificated and the&nbsp;pre-funded&nbsp;warrant, Series I Warrant and Series II Warrant included in such unit are immediately separable and will be issued separately in this offering.</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: justify; font-size: 10pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: justify; font-size: 10pt;">This prospectus also relates to the offering of shares of our common stock issuable upon exercise of the warrants included in the Class&nbsp;B Units and the&nbsp;pre-funded&nbsp;warrants.</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 55%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 45%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; text-align: justify; width: 55%;">For more information, see the section entitled &#8220;Description of Capital Stock&#8221; on page&nbsp;15 of this prospectus.</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216.7pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-0.7pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width: 45%; vertical-align: top;">Series I Warrants and Series II Warrants&nbsp; offered by us in this offering</td>
			<td style="vertical-align: top; width: 55%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: justify; font-size: 10pt;">Series I Warrants to purchase up to&nbsp;12,121,212 shares, which may be exercised beginning on their date of issuance. The Series I Warrants are exercisable until the eighteen month anniversary of the original issuance date. The Series I Warrants have an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock, subject to adjustment.&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: justify; font-size: 10pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: justify; font-size: 10pt;">Series II Warrants to purchase up to 12,121,212 shares, which may be exercised beginning on their date of issuance. The Series II Warrants are exercisable until the five year anniversary of the original issuance date. The Series II Warrants have an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock, subject to adjustment.&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 55%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 45%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; text-align: justify; width: 55%;">For more information, see the section entitled &#8220;Description of Capital Stock&#8221; on page&nbsp;15 of this prospectus.</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216.7pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-216.7pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">5</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width: 45%; vertical-align: top;">Common stock to be outstanding after this offering</td>
			<td style="vertical-align: top; text-align: justify; width: 55%;">16,814,502 shares, assuming all units offered in this Prospectus are sold and no sales of Class B Units including pre-funded warrants, which, if sold, would reduce the number of Class A Units including shares of common stock that we are offering on a one-for-one basis and assuming no exercise of any warrants issued in this offering.</td>
		</tr>
		<tr>
			<td style="width: 45%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 55%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 45%; vertical-align: top;">Use of proceeds</td>
			<td style="vertical-align: top; text-align: justify; width: 55%;">We intend to use the net proceeds from this offering to fund research and development of our lead product candidate, TSC, including clinical trial activities, and for general corporate purposes. See &#8220;Use of Proceeds.&#8221;</td>
		</tr>
		<tr>
			<td style="width: 45%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 55%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 45%; vertical-align: top;">Risk factors</td>
			<td style="vertical-align: top; text-align: justify; width: 55%;">You should read the &#8220;Risk Factors&#8221; section of this prospectus as well as all other information included in this prospectus, including the information in the documents incorporated by reference into this prospectus, for a discussion of certain of the factors to consider carefully before deciding to purchase any securities in this offering.</td>
		</tr>
		<tr>
			<td style="width: 45%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 55%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 45%; vertical-align: top;">National Securities Exchange Listing</td>
			<td style="vertical-align: top; width: 55%;">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;DFFN.&#8221;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216.7pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-216pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The number of shares of our common stock to be outstanding after this offering is based on 4,693,290 shares of common stock outstanding as of September&nbsp;30, 2019 and excludes as of that date:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:22pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">309,276 shares of common stock issuable upon the exercise of outstanding stock options under the Diffusion Pharmaceuticals Inc. 2015 Equity Incentive Plan, as amended (the &#8220;2015 Equity Plan&#8221;), at a weighted-average exercise price of $55.78 per share;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:22pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">3,469,825 shares of common stock issuable upon the exercise of outstanding warrants, at a weighted-average exercise price of $15.09&nbsp;per share; and</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:22pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">19,740 shares of common stock reserved for future issuance under the 2015 Equity Plan.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Unless otherwise indicated, all information contained in this prospectus assumes no sale of Class B Units, which, if sold, would reduce the number of Class A Units (and therefore the number of shares of common stock sold in this offering on a one-for-one basis) and no exercise of any warrants issued in this offering. Additionally, unless otherwise indicated, all share information contained in this prospectus reflects the completion on December 13, 2018, of a 1-to-15 reverse stock split (the &#8220;<u>Reverse Stock Split</u>&#8221;) of our common stock. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise would have been entitled to receive fractional shares of common stock had their holdings rounded up to the next whole share. Proportional adjustments were made to the Company&#8217;s outstanding warrants, stock options and other equity securities and to the 2015 Equity Incentive Plan, as amended, to reflect the Reverse Stock Split, in each case, in accordance with the terms thereof.</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">6</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>RISK FACTORS</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>Investing in our </i><i>securities</i><i> involves a high degree of risk. You should carefully consider the risks described below, together with the other information contained in this prospectus, including our financial statements and the related notes appearing at the end of this prospectus, before making your decision to invest in </i><i>our securities</i><i>. We cannot assure you that any of the events discussed in the risk factors below will not occur. These risks could have a material and adverse impact on our business, results of operations, financial condition and cash flows, and our future prospects would likely be materially and adversely affected. If that were to happen, the trading price of our common stock</i><i> </i><i>could decline, and you could lose all or part of your investment.</i><i> In addition, you should also carefully consider the other risks described under the heading &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for </i><i>the year ended December 31, 2018</i><i>, which </i><i>is</i><i> incorporated herein by reference</i><i>, </i><i>as updated by annual, quarterly and other reports and documents we file with the SEC after the date of this prospectus and that are incorporated by reference herein</i><i>. </i></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Risks Related to this Offering </b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b><i>We have significant discretion over the use of the net proceeds from this offering. </i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Assuming all units offered in this Prospectus are sold, our net proceeds from this offering are expected to be approximately $6.9 million, assuming no Class B Units are sold in place of Class A Units. We intend to use the net proceeds of this offering to fund research and development of our lead product candidate, TSC, including clinical trial activities, and for general corporate purposes. Accordingly, our management will have broad discretion as to the application of such proceeds. The proceeds shall be used to carry out our business plan, pay salaries to our employees, and satisfy all our expenses, foreseeable and unforeseeable. As is the case with any business, it should be expected that certain expenses unforeseeable to management at this juncture will arise in the future. There can be no assurance that management&#8217;s use of proceeds generated through this offering will prove optimal or translate into revenue or profitability for the Company. Investors are urged to consult with their attorneys, accountants and personal investment advisors prior to making any decision to invest in the Company.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b><i>Even if this offering is successful, we will need to raise additional capital in the future to continue operations, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations. </i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">To date, we have not sold, or received approval to sell, any pharmaceutical products. We do not expect to sell any pharmaceutical products for at least the next several years, if at all. Our net losses were approximately $18.4 million and $1.4 million for the years ended December&nbsp;31, 2018 and 2017, respectively, and our net losses attributable to common stockholders were approximately $26.6 million and $2.6 million for the years ended December&nbsp;31, 2018 and 2017, respectively. As of September&nbsp;30, 2019 and December 31, 2018, we had incurred cumulative net losses totaling approximately $88.0&nbsp;million and $79.9 million, respectively. Moreover, we expect that our net losses will continue and may increase for the foreseeable future. We may never generate sufficient product revenue (if any) to become profitable. We also expect to have quarter-to-quarter fluctuations in revenues, expenses, and losses, some of which could be significant.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Assuming all units offered in this Prospectus are sold, we estimate that we will receive net proceeds of approximately $6.9 million from the sale of the securities offered by us in this offering, based on the assumed public offering price of $0.66 per Class A Unit (the last reported sale price of our common stock on the NASDAQ Capital Market on November 7, 2019), assuming no Class B Units are sold in place of Class A Units, and after deducting the estimated placement agent&#8217;s fees and estimated offering expenses payable by us. In the event of a decrease in the net proceeds to us from this offering as a result of a decrease in the assumed public offering price per unit or the number of units offered by us, we may need to raise additional capital sooner than we anticipate or may need to scale back or eliminate certain of our development programs.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We will need to raise more money to complete our planned clinical trials, continue the research and development necessary to bring our products to market and to establish marketing and additional manufacturing capabilities. Notably, the proceeds raised in this offering will not be enough to complete our planned Phase 2 clinical trial of TSC for stroke or our Phase 3 clinical trial of TSC for treatment of glioblastoma multiforme. Additionally, we do not intend to commence our Phase 3 clinical trial of TSC for treatment of GBM prior to engaging in a strategic partnership. We may seek additional funds through public and private stock offerings, government contracts and grants, arrangements with corporate collaborators, borrowings under lines of credit or other sources. However, we may not be able to raise additional funds on acceptable terms, or at all. Conditions in the capital markets and the financial services industry may make equity and debt financing more difficult to obtain, and may negatively impact our ability to complete financing transactions. Any debt financing, if available, may involve restrictive covenants, such as limitations on our ability to incur additional indebtedness and other operating restrictions that could adversely impact our ability to conduct our business.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">7</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates or one or more of our research and development initiatives, reduce our workforce, license to others products or technologies that we otherwise would seek to commercialize ourselves or, ultimately, cease operations. The amount of money we may need would depend on many factors, including:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">The costs and progress of our research and development programs;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">The scope and results of our preclinical studies and clinical trials; and</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">The time and costs involved in: obtaining necessary regulatory approvals; filing, prosecuting and enforcing patent claims; scaling up our manufacturing capabilities; and the commercial arrangements we may establish.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b><i>An investment in our securities is speculative and there can be no assurance of any return on any such investment. </i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">An investment in our securities is speculative and there is no assurance that investors will obtain any return on their investment. Investors will be subject to substantial risks involved in an investment in the Company, including the risk of losing their entire investment.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b><i>There </i></b><b><i>will likely</i></b><b><i> be future sales of our securities or other dilution of our equity, which may adversely affect the market price of our common stock. </i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We are generally not restricted from issuing additional common stock, including any securities that are convertible into or exchangeable for, or that represent the right to receive, common stock. The market price of our common stock could decline as a result of sales of common stock or securities that are convertible into or exchangeable for, or that represent the right to receive, common stock after this offering or the perception that such sales could occur. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i><b>This is a best efforts offering, no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business plans.</b></i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The placement agent has agreed to use its reasonable best efforts to solicit offers to purchase the securities in this offering. The placement agent has no obligation to buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities. There is no required minimum number of securities that must be sold as a condition to completion of this offering. Because there is no minimum offering amount required as a condition to the closing of this offering, the actual offering amount, placement agent fees and proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth above. We may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to fund research and development of our lead product candidate, TSC, including clinical trial activities. Thus, we may not raise the amount of capital we believe is required for our operations in the short-term and may need to raise additional funds, which may not be available or available on terms acceptable to us.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b><i>If we cannot continue to satisfy the N</i></b><b><i>asdaq</i></b><b><i> Capital Market continued listing standards and other N</i></b><b><i>asdaq rules, our common s</i></b><b><i>tock could be delisted, which would harm our business, the trading price of our </i></b><b><i>common stock</i></b><b><i>, our ability to raise additional capital and the liquidity of the market for our </i></b><b><i>common stock</i></b><b><i>.</i></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Our common stock is currently listed on the Nasdaq Capital Market. To maintain the listing of our common stock on the Nasdaq Capital Market, we are required to meet certain listing requirements, including, among others, either: (i) a minimum closing bid price of $1.00 per share, a market value of publicly held shares (excluding shares held by our executive officers, directors and 10% or more stockholders) of at least $1 million and stockholders&#8217; equity of at least $2.5 million; or (ii) a minimum closing bid price of $1.00 per share, a market value of publicly held shares (excluding shares held by our executive officers, directors and 10% or more stockholders) of at least $1 million and a total market value of listed securities of at least $35 million.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">As of November 7, 2019, our closing price per share of common stock was less than $1.00 per share. There is no assurance that we regain compliance with the minimum closing price requirement and other listing requirements. In the event that our common stock is delisted from Nasdaq and is not eligible for quotation or listing on another market or exchange, trading of our common stock could be conducted only in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it could become more difficult to dispose of, or obtain accurate price quotations for, our common stock, and there would likely also be a reduction in our coverage by securities analysts and the news media, which could cause the price of our common stock to decline further.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><i><b>The pre-funded warrants, Series I Warrants and Series II Warrants are speculative in nature.</b></i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">None of the pre-funded warrants, Series I Warrants or Series II Warrants offered hereby confer any rights of common stock ownership on their holders, such as voting rights or the right to receive dividends, but rather merely represent the right to acquire shares of common stock at a fixed price. Specifically, commencing on the date of issuance, holders of the pre-funded warrants may acquire the common stock issuable upon exercise of such warrants at an exercise price of $0.001 per share of common stock and holders of the Series I Warrants and Series II Warrants may acquire the common stock issuable upon exercise of such warrants at an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. There can be no assurance that it will ever be profitable for holders of the pre-funded warrants to exercise the pre-funded warrants or the holders of the Series I Warrants or Series II Warrants to exercise the Series I Warrants or Series II Warrants, respectively.<b>&nbsp;</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i><b>Holders of the pre-funded warrants, Series I Warrants and Series II Warrants will have no voting rights&nbsp;as common stockholders until they acquire our common stock.</b></i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Until you acquire shares of our common stock upon exercise of the pre-funded warrants, Series I Warrants and Series II Warrants, you will have no voting rights with respect to our common stock issuable upon exercise of the pre-funded warrants, Series I Warrants or Series II Warrants. Upon exercise of your pre-funded warrants, Series I Warrants or Series II Warrants, you will be entitled to exercise all the voting rights of a common stockholder only as to matters for which the record date occurs after the exercise date.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>&nbsp;</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i><b>Significant holders or beneficial holders of our common stock may not be permitted to exercise pre-funded warrants, Series I Warrants or Series II Warrants that they hold.</b></i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The pre-funded warrants, Series I Warrants and Series II Warrants being offered hereby will prohibit a holder from exercising its pre-funded warrants, Series I Warrants or Series II Warrants if doing so would result in such holder (together with such holder&#8217;s affiliates and any other persons acting as a group together with such holder or any of such holder&#8217;s affiliates) beneficially owning more than 4.99% of our common stock outstanding immediately after giving effect to the exercise, provided that, at the election of a holder and notice to us, such beneficial ownership limitation shall be 9.99% of our common stock outstanding immediately after giving effect to the exercise. As a result, if you hold a significant amount of our securities, you may not be able to exercise your pre-funded warrants, Series I Warrants or Series II Warrants for shares of our common stock, in whole or in part, at a time when it would be financially beneficial for you to do so.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>&nbsp;</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i><b>There is no public market for the pre-funded warrants, Series I Warrants or Series II Warrants</b></i> <i><b>to purchase shares of common stock being offered in this offering.</b></i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">There is no established public trading market for the pre-funded warrants, Series I Warrants or Series II Warrants being offered in this offering, and we do not expect a market to develop. In addition, we do not intend to apply to list the pre-funded warrants, Series I Warrants or Series II Warrants on any national securities exchange or other trading system, including the Nasdaq Capital&nbsp;Market. Without an active market, the liquidity of the pre-funded warrants, Series I Warrants or Series II Warrants will be limited.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>&nbsp;</i></b></p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">9</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We may be limited in our ability to utilize, or may not be able to utilize, net operating loss carryforwards to reduce our future tax liability as a result of this offering.</i></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:0pt;">As disclosed in our most recent Annual Report on Form&nbsp;10-K, under Section 382 of Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss (&#8220;NOL&#8221;) carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change income may be limited.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We believe that our reverse merger in January 2016 and other transactions that have occurred triggered an &#8220;ownership change&#8221; limitation that significantly limited our ability to utilize our NOL carryforwards. Our 2017, 2018 and 2019 financing transactions may have also triggered an ownership change, which could further limit our ability to utilize our NOL carryforwards. We have yet to determine this potential limitation. This offering may, alone or in conjunction with other changes in our stock ownership that we cannot control, result in an additional ownership change for purposes of Section&nbsp;382. We may also experience ownership changes in the future as a result of strategic transactions or partnerships, equity offerings and other shifts in our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change NOL carryforwards and other deferred tax assets to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, similar limitations may apply at the state level and there may be periods during which the use of NOL carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><i><b>An investment in the pre-funded warrants, Series I Warrants, Series II Warrants and our common stock has numerous tax consequences.</b></i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">There are numerous tax consequences to investors as a result of their investment in the Company. We encourage investors to&nbsp;seek advice from competent tax advisors as to the consequences of an investment in our pre-funded warrants, Series I Warrants, Series II Warrants and common stock (See &#8220;Material U.S. Federal Income Tax Considerations&#8221;).</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b><i>The Bylaws of the Company include a forum selection clause, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.</i></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Our Bylaws (the &#8220;Bylaws&#8221;) require that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim for breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our Certificate of Incorporation or our Bylaws or (iv) any action asserting a claim governed by the internal affairs doctrine, in each case subject to said Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">This exclusive forum provision will not apply to claims under the Exchange Act, but will apply to other state and federal law claims including actions arising under the Securities Act (although our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder).&nbsp; Section 22 of the Securities Act, however, creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.&nbsp; Accordingly, there is uncertainty as to whether a court would enforce such a forum selection provision as written in connection with claims arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to the foregoing provisions. This forum selection provision in our Bylaws may limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents, which may discourage lawsuits against us and such persons. It is also possible that, notwithstanding the forum selection clause included in our Bylaws, a court could rule that such a provision is inapplicable or unenforceable.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">This prospectus and the other information and documents incorporated by reference herein include forward-looking statements. We may, in some cases, use terms such as &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;approximately&#8221; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements appear in and are incorporated by reference into a number of places throughout this prospectus and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, our intellectual property position, the degree of clinical utility of our products, particularly in specific patient populations, expectations regarding clinical trial data, our ability to commercialize our product candidates, our results of operations, cash needs, financial condition, liquidity, prospects, growth and strategies, the industry in which we operate and the trends that may affect the industry or us.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in or incorporated by reference into this prospectus, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in and incorporated by reference into this prospectus. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in and incorporated by reference into this prospectus, they may not be predictive of results or developments in future periods.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Actual results could differ materially from our forward-looking statements due to a number of factors, including risks related to:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our ability to obtain additional financing;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our estimates regarding expenses, capital requirements and needs for additional financing;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the success and timing of our preclinical studies and clinical trials;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">&#8226;</td>
			<td style="vertical-align:top;">the difficulties in obtaining and maintaining regulatory approval of our products and product candidates, and the labeling under any approval we may obtain;</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our plans and ability to develop and commercialize our product candidates;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our failure to recruit or retain key scientific or management personnel or to retain our executive officers;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the accuracy of our estimates of the size and characteristics of the potential markets for our product candidates and our ability to serve those markets;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">regulatory developments in the United States and foreign countries;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the rate and degree of market acceptance of any of our product candidates;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">obtaining and maintaining intellectual property protection for our product candidates and our proprietary technology;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our ability to operate our business without infringing the intellectual property rights of others;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">recently enacted and future legislation regarding the healthcare system;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our ability to satisfy the continued listing requirements of the Nasdaq Capital Market or any other exchange that our securities may trade on in the future;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">11</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our ability to continue as a going concern;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the success of competing products that are or may become available; and</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the performance of third parties, including contract research organizations and manufacturers.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">You should also read carefully the factors described in the &#8220;Risk Factors&#8221; section contained in this prospectus and incorporated by reference herein from our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 as updated by annual, quarterly and other reports and documents we file with the SEC after the date of this prospectus and that are incorporated by reference herein to better understand the risks and uncertainties inherent in our business and underlying any forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements contained in or incorporated by reference into this prospectus will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Any forward-looking statements that we make in or incorporate by reference into this prospectus speak only as of the date of such statement, and, except as required by applicable law, we undertake no obligation to update such statements to reflect events or circumstances after the date of this prospectus or to reflect the occurrence of unanticipated events. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">12</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>USE OF PROCEEDS</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Assuming all units offered in this Prospectus are sold, we estimate that we will receive net proceeds of approximately $6.9 million from the sale of the securities offered by us in this offering, based on the assumed public offering price of $0.66 per Class A Unit (the last reported sale price of our common stock on the Nasdaq Capital Market on November 7, 2019), assuming no sales of Class B Units, which, if sold, would reduce the number of Class A Units that we are offering on a one-for-one basis, and after deducting the estimated Placement Agent&#8217;s fees and estimated offering expenses payable by us. However, because this is a best efforts offering and there is no minimum offering amount required as a condition to the closing of this offering, the actual offering amount, Placement Agent&#8217;s fees and net proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth on the cover page of this prospectus.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">A $0.10 increase (decrease) in the assumed public offering price of $0.66 per Class A Unit would increase (decrease) the net proceeds to us from this offering by approximately $1.1&nbsp;million, assuming that the number of Class A Units offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated Placement Agent&#8217;s fees and estimated offering expenses payable by us.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Similarly, a one million unit increase (decrease) in the number of&nbsp;Class A Units&nbsp;offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us by approximately $601,000, assuming the assumed public offering price of $0.66 per Class A Unit remains the same, and after deducting estimated Placement Agent&#8217;s fees and estimated offering expenses payable by us.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We currently intend to use the net proceeds from this offering to fund research and development of our lead product candidate, TSC, including clinical trial activities, and for general corporate purposes. See &#8220;Risk Factors&#8221; in this prospectus and in our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2018, incorporated by reference herein, as updated by annual, quarterly and other reports and documents we file with the SEC after the date of this prospectus and that are incorporated by reference herein, for a discussion of certain risks that may affect our intended use of the net proceeds from this offering, including that we will need to raise additional capital in the future to complete the development of TSC and our other product candidates.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> The following table sets forth the expected uses of proceeds assuming the sale of 25%, 50%, 75% and 100% of the Class A Units offered hereby. </p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;">

		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> <b>&#8203;</b> </p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <b>&nbsp;</b> </td>
			<td id=".amt.2" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"> <b>25%</b> </td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; text-align: center;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"> <b>&nbsp;</b> </td>
			<td id=".amt.3" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"> <b>50%</b> </td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; text-align: center;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"> <b>&nbsp;</b> </td>
			<td id=".amt.4" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"> <b>75%</b> </td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; text-align: center;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"> <b>&nbsp;</b> </td>
			<td id=".amt.5" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"> <b>100%</b> </td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> <b>Placement agent fees and estimated offering expenses </b> </p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <b>$</b> </td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <b>515,000</b> </td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <b>$</b> </td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <b>695,000</b> </td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <b>$</b> </td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <b>875,000</b> </td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <b>$</b> </td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <b>1,055,000</b> </td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> <b>Research and development of our lead product candidate, TSC, including clinical trial activities, and for general corporate purposes</b> </p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <b>&nbsp;</b> </td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <b>1,485,000</b> </td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <b>&nbsp;</b> </td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <b>3,305,000</b> </td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <b>&nbsp;</b> </td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <b>5,125,000</b> </td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <b>&nbsp;</b> </td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <b>6,945,000</b> </td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> <b>Gross proceeds </b> </p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <b>$</b> </td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <b>2,000,000</b> </td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <b>$</b> </td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <b>4,000,000</b> </td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <b>$</b> </td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <b>6,000,000</b> </td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <b>$</b> </td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <b>8,000,000</b> </td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> We anticipate the estimated $8.0 million of gross proceeds, assuming all units offered by this Prospectus are sold, but no warrants offered hereby are exercised, will be sufficient to fund our planned operations and research and development of TSC through at least the third quarter of 2020. Our expected use of net proceeds from this offering represents our current intentions based upon our present plans and business condition. As of the date of this prospectus, we cannot currently allocate specific percentages of the net proceeds that we may use for research and development of our lead product candidate, TSC, including clinical trial activities, and for general corporate purposes, and we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering, or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual use of the net proceeds will vary depending on numerous factors, including our ability to obtain additional financing, the progress, cost and results of our preclinical and clinical development programs, and whether we are able to enter into future licensing or collaboration arrangements. We may find it necessary or advisable to use the net proceeds for other purposes, and our management will have broad discretion in the application of the net proceeds, and investors will be relying on our judgment regarding the application of the net proceeds from this offering. </p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Pending the use of the net proceeds from this offering, we intend to invest the net proceeds in short-term, investment-grade, interest-bearing securities or certificates of deposit.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">13</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>CAPITALIZATION</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The following table sets forth cash and capitalization as of September&nbsp;30, 2019:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">on an actual basis;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">on an as adjusted basis to give effect to the assumed issuance and sale of&nbsp;all Class A Units in this offering at the assumed public offering price of $0.66 per Class A Unit (but excluding shares of common stock to be issued and any proceeds received upon exercise of the Series I Warrants or Series II Warrants) (the last reported sale price of our common stock on the Nasdaq Capital Market on November 7, 2019), assuming no sales of Class B&nbsp;Units, which, if sold, would reduce the number Class A Units (and therefore the number of shares of common stock that we are offering) on a one-for-one basis, after deducting estimated Placement Agent&#8217;s fees, and estimated offering expenses payable by us.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 27pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><br>
			<b>(unaudited)</b></p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" nowrap="true" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0); width: 0%; padding: 0px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Actual as of </b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>September 30, 2019 </b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" nowrap="true" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0); width: 0%; padding: 0px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>As Adjusted as of </b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>September 30, 2019</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,139,770</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,084,770</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.B2" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B2" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".trail.B2" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.B3" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.B3" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B3" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".trail.B3" style="padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stockholders&#8217; equity:</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Common stock, par value $0.001 per share; 1,000,000,000 shares authorized, 4,693,290 shares issued and outstanding actual; 1,000,000,000 shares authorized, 16,814,502 shares issued and outstanding as adjusted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,694</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,815</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Additional paid-in capital</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">101,486,119</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">108,418,998</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accumulated deficit</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(87,971,998</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(87,971,998</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.B2" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B2" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".trail.B2" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.B3" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.B3" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B3" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".trail.B3" style="padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total stockholders' equity</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,518,815</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20,463,815</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.B2" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B2" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".trail.B2" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.B3" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.B3" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B3" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".trail.B3" style="padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total capitalization</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,518,815</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,463,815</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The number of shares of our common stock to be outstanding after this offering is based on 4,693,290 shares of common stock outstanding as of September&nbsp;30, 2019 and excludes as of that date:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:22pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">309,276 shares of common stock issuable upon the exercise of outstanding stock options under the 2015 Equity Plan at a weighted-average exercise price of $55.78 per share;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:22pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">3,469,825 shares of common stock issuable upon the exercise of outstanding warrants, at a weighted-average exercise price of $15.09&nbsp;per share; and</p>
			</td>
		</tr>
		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:22pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:22pt;vertical-align:top;">&#8226;</td>
			<td style="vertical-align: top; text-align: justify;">19,740 shares of common stock reserved for future issuance under the 2015 Equity Plan.</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">14</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>DESCRIPTION OF CAPITAL STOCK</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Company Capitalization</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Our authorized capital stock consists of 1,000,000,000 shares of common stock and 30,000,000 shares of preferred stock, $0.001 par value, all of which remains undesignated. The following summary is qualified in its entirety by reference to our Certificate of Incorporation, as amended, a copy of which is filed as an exhibit to our previous filings with the SEC and incorporated herein by reference.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Common Stock</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>Authorized</i>. We are authorized to issue 1,000,000,000 shares of common stock, of which 4,693,290 shares were issued and outstanding as of September&nbsp;30, 2019. We may amend from time to time our Certificate of Incorporation to increase the number of authorized shares of common stock. Any such amendment would require the approval of the holders of a majority of the voting power of the shares entitled to vote thereon.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>Voting Rights</i>. For all matters submitted to a vote of stockholders, each holder of common stock is entitled to one vote for each share registered in the holder&#8217;s name on our books. Our common stock does not have cumulative voting rights. At all meetings of the stockholders, except where otherwise provided by law, the Certificate of Incorporation or Bylaws, the presence, in person or by proxy duly authorized, of the holders of a majority of the outstanding shares of common stock entitled to vote constitutes a quorum for the transaction of business. Except as otherwise provided by law or by the Certificate of Incorporation or Bylaws, in all matters other than the election of directors, the affirmative vote of the majority of shares of common stock present in person or represented by proxy at the meeting and entitled to vote generally on the subject matter shall be the act of the stockholders. Except as otherwise provided by law, the Certificate of Incorporation or Bylaws, directors are elected by a plurality of the votes of the shares of common stock present in person or represented by proxy at the meeting and entitled to vote generally on the election of directors.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>Dividends</i>. Subject to limitations under Delaware law and any preferences that may be applicable to any then outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared by our Board out of legally available funds.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>Liquidation</i>. Upon our liquidation, dissolution or winding up, the holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities of our company, subject to any prior rights of any preferred stock then outstanding.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>Fully Paid and Non-assessable</i>. All shares of our outstanding common stock are fully paid and non-assessable and any additional shares of common stock that we issue will be fully paid and non-assessable.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>Other Rights and Restrictions</i>. Holders of common stock do not have preemptive or subscription rights, and they have no right to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to common stock. The rights, preferences and privileges of common stockholders are subject to the rights of the stockholders of any series of preferred stock which we may designate in the future. Our Certificate of Incorporation and Bylaws do not restrict the ability of a holder of common stock to transfer the holder&#8217;s shares of common stock.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>Listing</i>. Our common stock is quoted on the Nasdaq Capital Market under the symbol &#8220;DFFN.&#8221; As of November 7, 2019, there were 515 record holders of our common stock.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>Transfer Agent and Registrar</i>. The transfer agent and registrar for common stock is Computershare Investor Services, LLC, 250 Royall Street, Canton, Massachusetts, telephone number: 1-800-942-5909.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Pre-Funded Warrants</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>The material terms and provisions of the pre-funded warrants being issued in this offering are summarized below. The following description is subject to, and qualified in its entirety by, the form of pre-funded warrant which is filed herewith as an exhibit. You should review the form of pre-funded warrant for a complete description of the terms and conditions applicable to the pre-funded warrants. See &#8220;Information Incorporated by Reference and Available Information&#8221; below.</i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">15</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>Duration and Exercise Price.</i>&nbsp;Each pre-funded warrant offered hereby will have an initial exercise price per share equal to $0.001. The pre-funded warrants will be immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and the exercise price.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>&nbsp;</i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>Exercisability.&nbsp;</i>The pre-funded warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of the pre-funded warrant to the extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days&#8217; prior notice from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder&#8217;s pre-funded warrants up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the pre-funded warrants. Purchasers of pre-funded warrants in this offering may also elect prior to the issuance of the pre-funded warrants to have the initial exercise limitation set at 9.99% of our outstanding common stock.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>Transferability</i>.&nbsp;&nbsp;&nbsp;&nbsp;Subject to applicable laws, the pre-funded warrants are separately tradeable immediately after issuance at the option of the holders and may be transferred at the option of the holders upon surrender of the pre-funded warrant to us together with the appropriate instruments of transfer.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>No Listing</i>.&nbsp;&nbsp;&nbsp;&nbsp;There is no established public trading market for the pre-funded warrants and we do not expect a market to develop. In addition, we do not intend to apply for listing of the pre-funded warrants on any securities exchange or trading system. Without an active market, the liquidity of the pre-funded warrants will be limited.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>Fundamental Transactions</i>.&nbsp;&nbsp;&nbsp;&nbsp;In the event of a &#8220;fundamental transaction,&#8221; as defined in the pre-funded warrants and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holders of the pre-funded warrants will be entitled to receive upon exercise of the pre-funded warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the pre-funded warrants immediately prior to such fundamental transaction.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>Cashless Exercise.</i>&nbsp;If, at the time a holder exercises its pre-funded warrants, a registration statement registering the issuance of the shares of common stock underlying the pre-funded warrants under the Securities Act is not then effective or available, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the pre-funded warrants.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>Rights as a Stockholder</i>.&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided in the pre-funded warrant or by virtue of a holder&#8217;s ownership of shares of our common stock, the holders of the pre-funded warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their pre-funded warrants.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>Amendments</i>.&nbsp;&nbsp;&nbsp;&nbsp;Amendments and waivers of the terms of the pre-funded warrants require the written consent of the holders of pre-funded warrants representing not less than a majority&nbsp;of the shares issuable upon exercise of the pre-funded warrants then outstanding and us, as well as any pre-funded warrant holder that would be disproportionately and materially adversely impacted by the amendment.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>No Fractional Shares</i>.&nbsp;&nbsp;&nbsp;&nbsp;No fractional shares or scrip representing fractional shares shall be issued upon the exercise of the pre-funded warrants. As to any fraction of a share which the holder would otherwise be entitled to purchase upon such exercise, we shall or shall cause, at our option, the payment of a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price of the pre-funded warrant per whole share or round such fractional share up to the nearest whole share.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">16</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>Series I Warrants </b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>The material terms and provisions of the Series I Warrants being issued in this offering are summarized below. The following description is subject to, and qualified in its entirety by, the form of Series I Warrant which is filed herewith as an exhibit. You should review the form of Series I Warrant for a complete description of the terms and conditions applicable to the Series I Warrant.. See &#8220;Information Incorporated by Reference and Available Information&#8221; below.</i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>General</i>.&nbsp;&nbsp;&nbsp;&nbsp;Each purchaser of Class A Units or Class B Units will receive a Series I Warrant to purchase one share of common stock for each unit purchased in the offering.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>Exercisability</i>.&nbsp;&nbsp;&nbsp;&nbsp;The Series I Warrants may be exercised at any time on or after their date of issuance, will have an exercise price of $&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; per share and are exercisable until the eighteen month anniversary of the date of issuance. The Series I Warrants will be exercisable, at the option of each holder, in whole or in part by delivering a duly executed exercise notice to us accompanied by payment in full for the number of shares of our common stock purchased upon such exercise. The exercise price of the Series I Warrant is subject to adjustment in the event of stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>Exercise Limitations</i>.&nbsp;&nbsp;&nbsp;&nbsp;A holder of a Series I Warrant will not have the right to exercise any portion of the Series I Warrant if the holder (together with its affiliates) would beneficially own in excess of 4.99% (or, at election of holder, 9.99%) of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Series I Warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon notice to us provided that any increase shall not be effective until 61 days following notice to us.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>Transferability</i>.&nbsp;&nbsp;&nbsp;&nbsp;Subject to applicable laws, the Series I Warrants are separately tradeable immediately after issuance at the option of the holders and may be transferred at the option of the holders upon surrender of the Series I Warrant to us together with the appropriate instruments of transfer.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>No Listing</i>.&nbsp;&nbsp;&nbsp;&nbsp;There is no established public trading market for the Series I Warrants and we do not expect a market to develop. In addition, we do not intend to apply for listing of the Series I Warrants on any securities exchange or trading system. Without an active market, the liquidity of the Series I Warrants will be limited.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>Fundamental Transactions</i>.&nbsp;&nbsp;&nbsp;&nbsp;In the event of a &#8220;fundamental transaction,&#8221; as defined in the warrant agreement and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holders of the Series I Warrants will be entitled to receive upon exercise of the Series I Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Series I Warrants immediately prior to such fundamental transaction.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Additionally, as more fully described in the Series I Warrants, in the event of certain fundamental transactions, the holders of the Series I Warrants will be entitled to receive consideration in an amount equal to the Black Scholes value of the Series I Warrants on the date of the consummation of such fundamental transaction.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>Cashless Exercise</i>.&nbsp;&nbsp;&nbsp;&nbsp;If, at the time a holder exercises its Series I Warrant, there is no effective registration statement registering, or the prospectus contained therein is not available for an issuance of the shares underlying the Series I Warrant to the holder, and the holder is not able to sell the shares issuable upon exercise of the Series I Warrant without limitations on volume pursuant to Rule&nbsp;144, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of our common stock determined according to a formula set forth in the Series I Warrant. In the event of a cashless exercise, if we fail to timely deliver the shares underlying the Series I Warrant, we will be subject to certain buy-in provisions.&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>Rights as a Stockholder</i>.&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided in the Series I Warrant or by virtue of a holder&#8217;s ownership of shares of our common stock, the holders of the Series I Warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their Series I Warrants.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>Amendments</i>.&nbsp;&nbsp;&nbsp;&nbsp;Amendments and waivers of the terms of the Series I Warrants require the written consent of the holders of Series I Warrants representing not less than a majority&nbsp;of the shares issuable upon exercise of the Series I Warrants then outstanding and us, as well as any Series I Warrant holder that would be disproportionately and materially adversely impacted by the amendment.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">17</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>No Fractional Shares</i>.&nbsp;&nbsp;&nbsp;&nbsp;No fractional shares or scrip representing fractional shares shall be issued upon the exercise of the Series I Warrants. As to any fraction of a share which the holder would otherwise be entitled to purchase upon such exercise, we shall or shall cause, at our option, the payment of a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price of the Series I Warrant per whole share or round such fractional share up to the nearest whole share.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>Series II Warrants </b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>The material terms and provisions of the Series II Warrants being issued in this offering are summarized below. The following description is subject to, and qualified in its entirety by, the form of Series II Warrant which is filed herewith as an exhibit. You should review the form of Series II Warrant for a complete description of the terms and conditions applicable to the Series II Warrant.&nbsp;See &#8220;Information Incorporated by Reference and Available Information&#8221; below.</i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>General</i>.&nbsp;&nbsp;&nbsp;&nbsp;Each purchaser of Class A Units or Class B Units will receive a Series II Warrant to purchase one share of common stock for each unit purchased in the offering.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>Exercisability</i>.&nbsp;&nbsp;&nbsp;&nbsp;The Series II Warrants may be exercised at any time on or after their date of issuance, will have an exercise price of $&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; per share and are exercisable until the five year anniversary of the date of issuance. The Series II Warrants will be exercisable, at the option of each holder, in whole or in part by delivering a duly executed exercise notice to us accompanied by payment in full for the number of shares of our common stock purchased upon such exercise. The exercise price of the Series II Warrant is subject to adjustment in the event of stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>Exercise Limitations</i>.&nbsp;&nbsp;&nbsp;&nbsp;A holder of a Series II Warrant will not have the right to exercise any portion of the Series II Warrant if the holder (together with its affiliates) would beneficially own in excess of 4.99% (or, at election of holder, 9.99%) of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Series II Warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon notice to us provided that any increase shall not be effective until 61 days following notice to us.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>Transferability</i>.&nbsp;&nbsp;&nbsp;&nbsp;Subject to applicable laws, the Series II Warrants are separately tradeable immediately after issuance at the option of the holders and may be transferred at the option of the holders upon surrender of the Series II Warrant to us together with the appropriate instruments of transfer.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>No Listing</i>.&nbsp;&nbsp;&nbsp;&nbsp;There is no established public trading market for the Series II Warrants and we do not expect a market to develop. In addition, we do not intend to apply for listing of the Series II Warrants on any securities exchange or trading system. Without an active market, the liquidity of the Series II Warrants will be limited.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>Fundamental Transactions</i>.&nbsp;&nbsp;&nbsp;&nbsp;In the event of a &#8220;fundamental transaction,&#8221; as defined in the warrant agreement and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holders of the Series II Warrants will be entitled to receive upon exercise of the Series II Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Series II Warrants immediately prior to such fundamental transaction.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Additionally, as more fully described in the Series II Warrants, in the event of certain fundamental transactions, the holders of the Series II Warrants will be entitled to receive consideration in an amount equal to the Black Scholes value of the Series II Warrants on the date of the consummation of such fundamental transaction.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>Cashless Exercise</i>.&nbsp;&nbsp;&nbsp;&nbsp;If, at the time a holder exercises its Series II Warrant, there is no effective registration statement registering, or the prospectus contained therein is not available for an issuance of the shares underlying the Series II Warrant to the holder, and the holder is not able to sell the shares issuable upon exercise of the Series II Warrant without limitations on volume pursuant to Rule&nbsp;144, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of our common stock determined according to a formula set forth in the Series II Warrant. In the event of a cashless exercise, if we fail to timely deliver the shares underlying the Series II Warrant, we will be subject to certain buy-in provisions.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">18</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>Rights as a Stockholder</i>.&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided in the Series II Warrant or by virtue of a holder&#8217;s ownership of shares of our common stock, the holders of the Series II Warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their Series II Warrants.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>Amendments</i>.&nbsp;&nbsp;&nbsp;&nbsp;Amendments and waivers of the terms of the Series II Warrants require the written consent of the holders of Series II Warrants representing not less than a majority&nbsp;of the shares issuable upon exercise of the Series II Warrants then outstanding and us, as well as any Series II Warrant holder that would be disproportionately and materially adversely impacted by the amendment.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>No Fractional Shares</i>.&nbsp;&nbsp;&nbsp;&nbsp;No fractional shares or scrip representing fractional shares shall be issued upon the exercise of the Series II Warrants. As to any fraction of a share which the holder would otherwise be entitled to purchase upon such exercise, we shall or shall cause, at our option, the payment of a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price of the Series II Warrant per whole share or round such fractional share up to the nearest whole share.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Undesignated Preferred Stock</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">As of September&nbsp;30, 2019, no shares of preferred stock of the Company were issued or outstanding. Our Certificate of Incorporation authorizes our board of directors to provide for the issuance of up to 30,000,000 shares of preferred stock in one or more series and to fix the preferences, powers and relative, participating, optional or other special rights, and qualifications, limitations or restrictions thereof, including the dividend rate, conversion rights, voting rights, redemption rights and liquidation preference, and to fix the number of shares to be included in any such series without any further vote or action by our stockholders. Any preferred stock so issued may rank senior to our common stock with respect to the payment of dividends or amounts upon liquidation, dissolution or winding up, or both. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change in control of our company without further action by the stockholders and may adversely affect the voting and other rights of the holders of common stock. The issuance of preferred stock with voting and conversion rights may adversely affect the voting power of the holders of common stock, including the loss of voting control to others. At present, we have no plans to issue any preferred stock.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Anti-Takeover Provisions</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b><i>Delaware Anti-Takeover Law</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We are subject to Section&nbsp;203 of the DGCL. Section&nbsp;203 generally prohibits a public Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years after the date of the transaction in which the person became an interested stockholder, unless:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (a)&nbsp;shares owned by persons who are directors and also officers of the corporation and (b)&nbsp;shares issued under employee stock plans under which employee participants do not have the right to determine whether shares held subject to the plan will be tendered in a tender or exchange offer; or</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66&nbsp;2&#8260;3% of the outstanding voting stock that is not owned by the interested stockholder.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Section&nbsp;203 defines a business combination to include:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">any merger or consolidation involving the corporation and the interested stockholder;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">19</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">any transaction involving the corporation that has the effect of increasing the proportionate share of its stock owned by the interested stockholder; or</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In general, Section&nbsp;203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Warrants and Stock Options Issued and Outstanding</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">As of September&nbsp;30, 2019, the Company had the following warrants outstanding to acquire shares of its common stock:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:bottom;width:56.6%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:12.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Outstanding</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:16.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Range of exercise </b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>price per share</b></p>
			</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:1%;">&nbsp;</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:13.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Expiration </b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>dates</b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:56.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Common stock warrants issued prior to 2016</p>
			</td>
			<td style="vertical-align:bottom;border-bottom: 1px #000000;;width:11.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">1,667</p>
			</td>
			<td style="vertical-align:top;border-bottom: 1px #000000;;width:0.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:16.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">$562.50</p>
			</td>
			<td style="vertical-align:bottom;width:1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:13.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 2019</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:56.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Common stock warrants issued in 2017</p>
			</td>
			<td style="vertical-align:bottom;width:11.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">903,870</p>
			</td>
			<td style="vertical-align:top;width:0.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:16.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">$33.30</p>
			</td>
			<td style="vertical-align:bottom;width:1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:13.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">March 2022</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:56.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Common stock warrants issued in 2018</p>
			</td>
			<td style="vertical-align:bottom;width:11.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">1,181,375</p>
			</td>
			<td style="vertical-align:top;width:0.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:16.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">$12.00 - $15.00</p>
			</td>
			<td style="vertical-align:bottom;width:1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:13.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">January 2023</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:56.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Common stock warrants issued in 2019</p>
			</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:11.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">1,382,913</p>
			</td>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:0.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:16.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">$5.00 - $6.11875</p>
			</td>
			<td style="vertical-align:bottom;width:1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:13.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2024</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:56.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;border-bottom:double 3px #000000;;width:11.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">3,469,825</p>
			</td>
			<td style="vertical-align:top;border-bottom:double 3px #000000;;width:0.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:16.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:13.3%;">&nbsp;</td>
		</tr>

</table>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Additionally, as of September&nbsp;30, 2019, we had 309,276 shares of common stock issuable upon the exercise of outstanding stock options under the 2015 Equity Plan at a weighted-average exercise price of $55.78 per share.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">20</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>PLAN OF DISTRIBUTION</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Pursuant to an engagement agreement dated October 7, 2019, we have engaged H.C. Wainwright &amp; Co., LLC, or the placement agent, to act as our exclusive placement agent in connection with this offering, on a reasonable best efforts basis, of our Class A Units and our Class B Units pursuant to this prospectus. The terms of this offering were subject to market conditions and negotiations between us, the placement agent and prospective investors. The engagement agreement does not give rise to any commitment by the placement agent to purchase any of our units, and the placement agent will have no authority to bind us by virtue of the engagement agreement. Further, the placement agent does not guarantee that it will be able to raise new capital in any prospective offering. The placement agent may engage sub-agents or selected dealers to assist with the offering.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We will enter into a securities purchase agreement directly with institutional investors in connection with this offering. Investors who do not enter into a securities purchase agreement shall rely solely on this prospectus in connection with the purchase of our securities in this offering.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We will deliver the securities underlying Class A Units and the Class B Units being issued to the investors upon receipt of investor funds for the purchase of the Class A Units and the Class B Units offered pursuant to this prospectus. We expect to deliver the shares of our common stock being offered pursuant to this prospectus on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2019.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">21</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>Fees and Expenses</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We have agreed to pay to the Placement Agent a cash fee equal to 8.0% of the aggregate gross proceeds raised in this offering. The following table shows the per Unit Placement Agent fees&nbsp;payable to the Placement Agent by us in connection with this offering.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 9pt;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Per Class A Unit</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Per Class B Unit</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Public offering price</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Placement Agent&#8217;s fees payable by us</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Proceeds, before expenses, to us</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We estimate the total expenses payable by us for this offering to be approximately $1.1 million, which amount includes (i)&nbsp;an placement agent&#8217;s fee&nbsp;of $640,000, assuming the purchase of all of the securities we are offering; (ii) a management fee equal to 1% of the aggregate gross proceeds raised in this offering; (iii)&nbsp;a $25,000 non-accountable expense allowance payable to the Placement Agent; (iv)&nbsp;reimbursement of the accountable expenses of the Placement Agent equal to $100,000 including the legal fees of the Placement Agent being paid by us (none of which has been paid in advance); (v)&nbsp;the Placement Agent&#8217;s clearing expenses in the amount of $10,000 in connection with this offering; and (vi) other estimated expenses of approximately $200,000 which include legal, accounting, printing costs and various fees associated with the registration and listing of our shares. In addition, we have agreed to issue the Placement Agent&#8217;s Warrants to the Placement Agent. See &#8220;Placement Agent&#8217;s Warrants&#8221; below for additional detail.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>Placement Agent&#8217;s Warrants</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We have agreed to issue to the Placement Warrants to purchase shares of our common stock which represent 5% of the number of Class A Units and Class B Units being sold in this offering. The Placement Agent&#8217;s Warrants will have a term of five years from the effective date of this prospectus and an exercise price per share equal to $&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which represents 125% of the public offering price for the Class A Units sold in this offering. Pursuant to FINRA Rule&nbsp;5110(g), the Placement Agent&#8217;s Warrants and any shares issued upon exercise of the Placement Agent&#8217;s Warrants shall not be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of the securities by any person for a period of 180&nbsp;days immediately following the date of effectiveness or commencement of sales of this offering, except the transfer of any security: (i)&nbsp;by operation of law or by reason of our reorganization; (ii)&nbsp;to any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so transferred remain subject to the lock-up restriction set forth above for the remainder of the time period; (iii)&nbsp;if the aggregate amount of our securities held by the Placement Agent or related persons does not exceed 1% of the securities being offered; (iv)&nbsp;that is beneficially owned on a pro rata basis by all equity owners of an investment fund, provided that no participating member manages or otherwise directs investments by the fund and the participating members in the aggregate do not own more than 10% of the equity in the fund; or (v)&nbsp;the exercise or conversion of any security, if all securities remain subject to the lock-up restriction set forth above for the remainder of the time period.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">22</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-10pt;"><b>Right of First Refusal</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We have also agreed to give the Placement Agent a twelve-month right of first refusal to act as our sole underwriter or placement agent for any further capital raising transactions undertaken by us; and a twelve-month tail fee equal to the cash and warrant compensation in this offering if any investor with which we have had substantive discussions with respect to this offering provides us with further capital during such twelve-month period following termination of our engagement.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>Lock-Up Agreements</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We and each of our officers and directors have agreed with the placement agent to be subject to a lock-up period of 90 days following the date of this prospectus. This means that, during the applicable lock-up period, we may not offer for sale, contract to sell, or sell any shares of our common stock or any securities convertible into, or exercisable or exchangeable for, shares of our common stock subject to certain customary exception such as issuing stock options to directors, officers, employees and consultants under our existing plan and issuances of shares issuable upon the exercise of our outstanding warrants, including the warrants issued pursuant to this Prospectus. The placement agent may, in its sole discretion and without notice, waive the terms of any of these lock-up agreements.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>Nasdaq Capital Market Listing</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Our stock is currently traded on the Nasdaq Capital Market under the symbol &#8220;DFFN.&#8221; On November 7, 2019, the last reported sale price of our common stock was $0.66 per share. We do not plan to list the pre-funded warrants, Series I Warrants, Series II Warrants or the Placement Agent&#8217;s Warrants on the Nasdaq Capital Market or any other securities exchange or trading market.</p>

<p style="margin: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">23</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-10pt;"><b>Indemnification</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We have agreed to indemnify the Placement Agent and specified other persons against some civil liabilities, including liabilities under the Securities Act, and the Securities Exchange Act of 1934, as amended, or the Exchange Act, and to contribute to payments that the Placement Agent may be required to make in respect of such liabilities.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>Regulation M</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The placement agent may be deemed to be an underwriter within the meaning of Section&nbsp;2(a)(11) of the Securities Act and any fees received by it and any profit realized on the sale of the securities by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. The placement agent will be required to comply with the requirements of the Securities Act and the Exchange Act including, without limitation, Rule&nbsp;10b-5&nbsp;and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of our securities by the placement agent. Under these rules and regulations, the placement agent may not (i)&nbsp;engage in any stabilization activity in connection with our securities; and (ii)&nbsp;bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until they have completed their participation in the distribution.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>Other Relationships</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The Placement Agent and its respective affiliates have in the past and may in the future engage in investment banking and other commercial dealings in the ordinary course of business with us or our affiliates. The Placement Agent has received, or may in the future receive, customary fees and commissions for these transactions.</p>

<p style="margin: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">24</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The following is a general discussion of the material U.S. federal income considerations applicable to the ownership and disposition of shares of our common stock and warrants acquired in this offering. This discussion is for general information only and is not tax advice. Accordingly, all prospective holders of our common stock and warrants should consult their own tax advisors with respect to the U.S. federal, state, local and non-U.S. tax consequences of the purchase, ownership and disposition of our common stock and warrants. This discussion is based on current provisions of the U.S. Internal Revenue Code of 1986, as amended, which we refer to as the Code, existing and proposed U.S. Treasury Regulations promulgated thereunder, current administrative rulings and judicial decisions, all as in effect as of the date of this prospectus, all of which are subject to change or to differing interpretation, possibly with retroactive effect. Any change could alter the tax consequences described in this prospectus. We assume in this discussion that each holder holds shares of our common stock and warrants as capital assets within the meaning of Section&nbsp;1221 of the Code (generally property held for investment).</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular holder in light of that holder&#8217;s individual circumstances, does not address the alternative minimum or Medicare contribution taxes, and does not address any aspects of U.S. state, local or non-U.S. taxes or any U.S. federal taxes other than income tax. This discussion also does not consider any specific facts or circumstances that may apply to a non-U.S. holder and does not address aspects of U.S. federal income taxation that may be applicable to investors that are subject to special tax rules, including without limitation:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">insurance companies;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">tax-exempt organizations;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">financial institutions;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">brokers or dealers in securities;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">regulated investment companies;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">real estate investment trusts;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">pension plans, individual retirement accounts and other tax deferred accounts;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">persons that mark their securities to market;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">controlled foreign corporations;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">passive foreign investment companies;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#8220;dual resident&#8221; corporations;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">persons that receive our common stock or warrants as compensation for the performance of services;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">owners that hold our common stock or warrants as part of a straddle, hedge, conversion transaction, synthetic security or other integrated investment;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">owners that own, or are deemed to own, more than 5% of our capital stock (except to the extent specifically set forth below);</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">persons that have a functional currency other than the U.S. dollar; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">certain U.S. expatriates.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">25</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In addition, this discussion does not address the tax treatment of partnerships or other pass-through entities for U.S. federal income tax purposes, or persons who hold our common stock or warrants through partnerships or other pass-through entities for U.S. federal income tax purposes. A partner in a partnership or other pass-through entity that will hold our common stock or warrants&nbsp;should consult his, her or its own tax advisor regarding the tax consequences of acquiring, holding and disposing of our common stock or warrants through a partnership or other pass-through entity, as applicable.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">There can be no assurance that the Internal Revenue Service, which we refer to as the IRS, will not challenge one or more of the tax consequences described herein. We have not obtained, nor do we intend to obtain, a ruling from the IRS with respect to the U.S. federal income tax consequences of the purchase, ownership or disposition of our common stock or warrants.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i><b>Allocation of Purchase Price Between Common Stock or Pre-Funded Warrant and Accompanying Series I Warrant and Series II Warrant to Purchase Our Common Stock</b></i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The Class&nbsp;A Units will not be certificated and the shares of common stock, Series I Warrants and Series II Warrants comprising such unit are immediately separable and will be issued separately in this offering. The Class&nbsp;B Units will not be certificated and the pre-funded warrants, Series I Warrants and Series II Warrants comprising such unit are immediately separable and will be issued separately in this offering. Each holder of our common stock or pre-funded warrants and Series I Warrants and Series II Warrants must allocate the purchase price paid by such holder for our Class A Units and Class B Units among the share of common stock or pre-funded warrant, the Series I Warrant and the Series II Warrant based on the relative fair market value of each. This allocation will establish a holder&#8217;s initial tax basis for U.S. federal income tax purposes in their shares of common stock or pre-funded warrants, Series I Warrants and Series II Warrants. We will not be providing holders with such allocation, and it is possible that different holders will reach different determinations regarding such allocation. A holder&#8217;s allocation of purchase price between common stock or pre-funded warrants, Series I Warrants and Series II Warrants is not binding on the IRS or the courts, and no assurance can be given that the IRS or the courts will agree with a holder&#8217;s allocation.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Accordingly, each prospective holder should consult their own tax advisor with respect to the risks associated with an allocation of the purchase price between our common stock or pre-funded warrants, Series I Warrants and Series II Warrants.</p>

<p style="margin: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Treatment of Pre-Funded Warrants</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Although it is not entirely free from doubt, a pre-funded warrant should be treated as a share of our common stock for U.S. federal income tax purposes and a holder of pre-funded warrants should generally be taxed in the same manner as a holder of common stock, as described below. Accordingly, no gain or loss should be recognized upon the exercise of a pre-funded warrant and, upon exercise, the holding period of a pre-funded warrant should carry over to the share of common stock received. Similarly, the tax basis of the pre-funded warrant should carry over to the share of common stock received upon exercise, increased by the exercise price of $0.001 per share. Each holder should consult his, her or its own tax advisor regarding the risks associated with the acquisition of pre-funded warrants pursuant to this offering (including potential alternative characterizations). The balance of this discussion generally assumes that the characterization described above is respected for U.S. federal income tax purposes.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;<b><i>U.S. Holders</i></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">This section applies to you if you are a &#8220;U.S. holder.&#8221; For purposes of this discussion, a &#8220;U.S. holder&#8221; means a beneficial owner of our common stock and warrants who is for U.S. federal income tax purposes: (i)&nbsp;an individual who is a citizen or resident of the United States; (ii)&nbsp;a corporation, or any other organization taxable as a corporation for U.S. federal income tax purposes, created or organized in the United States or under the laws of the United States or of any state thereof or the District of Columbia; (iii)&nbsp;an estate, the income of which is subject to U.S. federal income tax regardless of its source; or (iv)&nbsp;a trust if (1)&nbsp;a U.S. court is able to exercise primary supervision over the trust's administration and one or more U.S. persons have the authority to control all of the trust's substantial decisions or (2)&nbsp;the trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">26</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-10pt;"><b><i>Distributions on Our Common Stock</i></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Distributions, if any, on our common stock generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a tax-free return of the U.S. holder&#8217;s investment, up to such U.S. holder&#8217;s tax basis in the common stock. Any remaining excess will be treated as capital gain, subject to the tax treatment described below in &#8220;&#8212;Gain on Sale, Exchange or Other Taxable Disposition of Our Common Stock.&#8221; Dividends paid by us will generally be eligible for the reduced rates of tax for qualified dividend income allowed to individual U.S. holders and for the dividends received deduction allowed to corporate U.S. holders, in each case assuming that certain holding period and other requirements are satisfied.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i><b>Conversion of Series I Warrants or Series II Warrants into Our Common Stock</b></i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Except as discussed below with respect to the cashless exercise of a Series I Warrant or Series II Warrant (together, the &#8220;common warrants&#8221;), a U.S. holder will not recognize gain or loss on the conversion of common warrants into our common stock. A U.S. holder&#8217;s tax basis in the common stock received upon a conversion will equal the sum of (i)&nbsp;the initial tax basis of the common warrants converted and (ii)&nbsp;price paid upon exercise. The U.S. holder&#8217;s holding period for the common stock received upon exercise of the common warrants will begin on the date following the date of exercise of the common warrants and will not include the period during which the U.S. holder held the common warrants.</p>

<p style="margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The tax consequences of a cashless exercise of a common warrant are not clear under current U.S. tax law. A cashless exercise may be tax-free, either because the exercise is not a realization event or because the exercise is treated as a recapitalization for U.S. federal income tax purposes. In this case, a U.S. holder&#8217;s basis in the common stock received would equal the U.S. holder&#8217;s basis in the common warrant. If the cashless exercise were treated as a recapitalization, the holding period of the common stock would include the holding period of the common warrant.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">It is possible that a cashless exercise could be treated in part as a taxable exchange in which gain or loss would be recognized with respect to the common warrants surrendered to pay the exercise price for common warrants converted into common stock. In that event, a U.S. holder could be deemed to have surrendered only those common warrants used to satisfy the exercise price for an amount equal to the aggregate fair market value of the exercise price of the total number of common warrants to be exercised. The U.S. holder would recognize capital gain or loss in an amount equal to the difference between the amount deemed realized and the U.S. holder&#8217;s tax basis in the common warrants surrendered to pay the exercise price. In this case, a U.S. holder&#8217;s tax basis in the common stock received would equal the sum of the U.S. holder&#8217;s initial investment in the converted common warrants (i.e.,&nbsp;the portion of the U.S. holder&#8217;s purchase price for the shares of common stock that is allocated to the common warrants, as described above under &#8220;&#8212;Allocation of Purchase Price between Common Stock and Warrants&#8221;) and the exercise price of the common warrants converted. A U.S. holder&#8217;s holding period for the common stock would commence on the date following the date of exercise.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Due to the absence of authority on the U.S. federal income tax treatment of a cashless exercise, there can be no assurance which, if any, of the alternative tax consequences and holding periods described above would be adopted by the IRS or a court of law. Accordingly, U.S. holders should consult their own tax advisors regarding the tax consequences of a cashless exercise.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">If a common warrant is allowed to lapse unexercised, a U.S. holder generally will recognize a capital loss equal to such holder&#8217;s tax basis in the common warrant.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-10pt;"><b><i>Sale, Exchange or Other Taxable Disposition of Our Common Stock or Warrants</i></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Upon the sale, exchange, or other taxable disposition of our common stock or warrants, a U.S. holder will recognize gain or loss equal to the difference between the amount realized upon the disposition and the U.S. holder&#8217;s tax basis in the common stock or warrants sold or exchanged. Any gain or loss generally will be capital gain or loss, and will be long-term capital gain or loss if the U.S. holder&#8217;s holding period for the common stock or warrants exceeded one year at the time of the disposition. Certain U.S. holders (including individuals) are currently eligible for preferential rates of U.S. federal income taxation in respect of long-term capital gains. The deductibility of capital losses is subject to significant limitations.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">27</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-10pt;"><b><i>Information Reporting and Backup Withholding</i></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In general, information reporting requirements may apply to dividends paid to a U.S. holder on our common stock, and to the proceeds of the sale, exchange or other disposition of our common stock and warrants, unless the U.S. holder is an exempt recipient. Backup withholding may apply to such payments if the U.S. holder fails to provide a taxpayer identification number, a certification of exempt status or has been notified by the IRS that it is subject to backup withholding (and such notification has not been withdrawn). Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules will be allowed as a refund or a credit against a U.S. holder&#8217;s U.S. federal income tax liability provided the required information is timely furnished to the IRS.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-10pt;"><b>Non-U.S. Holders</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">This section applies to you if you are a &#8220;non-U.S. holder&#8221;. For purposes of this discussion, a &#8220;non-U.S. holder&#8221; means a person who is not a U.S. holder (as defined above under &#8220;U.S. Holders&#8221;).</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-10pt;"><b><i>Distributions on Our Common Stock</i></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Distributions, if any, on our common stock generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a tax-free return of the non-U.S. holder&#8217;s investment, up to such non-U.S. holder&#8217;s tax basis in the common stock. Any remaining excess will be treated as capital gain, subject to the tax treatment described below in &#8220;Gain on Sale, Exchange or Other Taxable Disposition of Our Common Stock.&#8221;&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Subject to the discussions below regarding backup withholding and the Foreign Account Tax Compliance Act, or FATCA, dividends paid to a non-U.S. holder generally will be subject to withholding of U.S. federal income tax at a rate of 30% of the gross amount or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#8217;s country of residence, unless such dividends are effectively connected with a trade or business conducted by a non U.S. holder within the U.S (as discussed below). A non-U.S. holder of our common stock who claims the benefit of an applicable income tax treaty between the United States and such holder&#8217;s country of residence generally will be required to provide a properly executed IRS Form&nbsp;W-8BEN or W-8BEN-E (or successor form), as applicable, and satisfy applicable certification and other requirements. Non-U.S. holders are urged to consult their own tax advisors regarding their entitlement to benefits under a relevant income tax treaty. A non-U.S. holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may be able to obtain a refund or credit of any excess amounts withheld by timely filing the required information with the IRS.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Subject to the discussions below regarding backup withholding and FATCA, dividends that are treated as effectively connected with a trade or business conducted by a non-U.S. holder within the United States and, if an applicable income tax treaty so provides, that are attributable to a &#8220;permanent establishment&#8221; or a &#8220;fixed base&#8221; maintained by the non-U.S. holder within the United States, are generally exempt from the 30% withholding tax if the non-U.S. holder satisfies applicable certification and disclosure requirements. U.S. effectively connected income, net of specified deductions and credits, is generally taxed at the same graduated U.S. federal income tax rates applicable to United States persons (as defined in the Code). Any U.S. effectively connected income received by a non-U.S. holder that is a corporation may also be subject to an additional &#8220;branch profits tax&#8221; at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#8217;s country of residence.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-10pt;"><b><i>Conversion of Common Warrants into Our Common Stock</i></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The U.S. federal income tax treatment of a non-U.S. holder&#8217;s exercise of a common warrant, or the lapse of a common warrant held by a Non-U.S. Holder, generally will correspond to the U.S. federal income tax treatment of the exercise or lapse of a common warrant by a U.S. Holder, as described under &#8220;U.S. Holders&#8212;Conversion of Common Warrants into Common Stock&#8221; above.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">28</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-10pt;"><b><i>Gain on Sale, Exchange or Other Taxable Disposition of Our Common Stock or Warrants</i></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Subject to the discussions below regarding backup withholding and FATCA, in general, a non-U.S. holder will not be subject to any U.S. federal income tax on any gain realized upon such holder&#8217;s sale, exchange or other taxable disposition of shares of our common stock or warrants unless:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">the gain is effectively connected with the non-U.S. holder&#8217;s conduct of a U.S. trade or business and, if an applicable income tax treaty so provides, is attributable to a &#8220;permanent establishment&#8221; or a &#8220;fixed base&#8221; maintained by such non-U.S. holder in the United States, in which case the non-U.S. holder generally will be taxed on such gain at the graduated U.S. federal income tax rates applicable to United States persons (as defined in the Code) and, if the non-U.S. holder is a foreign corporation, the branch profits tax described above in &#8220;Non-U.S. Holders&#8212;Distributions on Our Common Stock&#8221; also may apply to such gain;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">the non-U.S. holder is a nonresident alien individual who is present in the United States for 183&nbsp;days or more in the taxable year of the taxable disposition and certain other conditions are met, in which case the non-U.S. holder will be subject to a 30% tax (or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#8217;s country of residence) on the net gain derived from the taxable disposition, which may be offset by certain U.S. source capital losses of the non-U.S. holder, if any; or</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">we are, or have been, at any time during the five-year period preceding such taxable disposition (or the non-U.S. holder&#8217;s holding period, if shorter) a &#8220;U.S. real property holding corporation,&#8221; unless our common stock is regularly traded on an established securities market and the non-U.S. holder holds no more than 5% of our outstanding common stock, directly or indirectly, during the shorter of the 5-year period ending on the date of the taxable disposition or the period that the non-U.S. holder held our common stock. If we are determined to be a U.S. real property holding corporation and the foregoing exception does not apply, then a purchaser may withhold 15% of the proceeds payable to a non-U.S. holder from a sale of our common stock or warrants, and the non-U.S. holder generally will be taxed on its net gain derived from the disposition at the graduated U.S. federal income tax rates applicable to United States persons (as defined in the Code). Generally, a corporation is a U.S. real property holding corporation only if the fair market value of its U.S. real property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. Although there can be no assurance, we do not believe that we are, or have been, a U.S. real property holding corporation, or that we are likely to become one in the future. No assurance can be provided that our common stock will be regularly traded on an established securities market for purposes of the rules described above.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-10pt;"><b><i>Backup Withholding and Information Reporting</i></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We must report annually to the IRS and to each non-U.S. holder the gross amount of the distributions paid on our common stock to such holder and the tax withheld, if any, with respect to such distributions. Non-U.S. holders may have to comply with specific certification procedures to establish that the holder is not a United States person (as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on our common stock or warrants. Dividends paid to non-U.S. holders subject to the U.S. withholding tax, as described above in &#8220;Non-U.S. Holders&#8212;Distributions on Our Common Stock,&#8221; generally will be exempt from U.S. backup withholding.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Information reporting and backup withholding generally will apply to the proceeds of a disposition of our common stock and warrants by a non-U.S. holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the holder certifies its status as a non-U.S. holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a non-U.S. holder where the transaction is effected outside the United States through a non-U.S. office of a broker. However, for information reporting purposes, dispositions effected through a non-U.S. office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. Non-U.S. holders should consult their own tax advisors regarding the application of the information reporting and backup withholding rules to them.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Copies of information returns may be made available to the tax authorities of the country in which the non-U.S. holder resides or is incorporated under the provisions of a specific treaty or agreement.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a non-U.S. holder can be refunded or credited against the non-U.S. holder&#8217;s U.S. federal income tax liability, if any, provided that an appropriate claim is filed with the IRS.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">29</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-10pt;"><b>Withholding and Information Reporting Requirements&#8212;FATCA</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">FATCA may impose a U.S. federal withholding tax at a rate of 30% on payments of dividends on our common stock paid to certain foreign entities, unless (i)&nbsp;if the foreign entity is a &#8220;foreign financial institution,&#8221; such foreign entity undertakes certain due diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if the foreign entity is not a &#8220;foreign financial institution,&#8221; such foreign entity either certifies that it does not have any &#8220;substantial United States owners&#8221; (as defined in the Code) or furnishes identifying information regarding each substantial United States owner, or (iii)&nbsp;the foreign entity otherwise qualifies from an exemption these rules. Under applicable U.S. Treasury Regulations, withholding under FATCA currently applies to payments of dividends paid on our common stock. A Non-U.S. holder that is not subject to FATCA withholding generally may certify its exempt status by furnishing a properly executed IRS Form&nbsp;W-8BEN or Form&nbsp;W-8BEN-E (or successor form), as applicable. Under certain circumstances, a non-U.S. holder may be eligible for refunds or credits of the tax. Certain intergovernmental agreements between the United States and other countries may modify these rules. Non-U.S. holders should consult their own tax advisors regarding the possible implications of this legislation on their investment in our common stock and the entities through which they hold our common stock, including, without limitation, the process and deadlines for meeting the applicable requirements to prevent the imposition of the 30% withholding tax under FATCA.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">30</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>LEGAL MATTERS</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The validity of the securities being offered by this prospectus will be passed upon for us by Dechert LLP. The placement agent is being represented by Ellenoff Grossman &amp; Schole LLP, New York, New York.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>EXPERTS</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The consolidated financial statements of Diffusion Pharmaceuticals Inc. as of and for the years ended December 31, 2018 and 2017, have been incorporated by reference herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. The audit report covering the December 31, 2018 consolidated financial statements contains an explanatory paragraph that states that the Company has suffered recurring losses from operations, has limited resources available to fund current research and development activities, and will require substantial additional financing to continue to fund its research and development activities that raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>WHERE YOU CAN FIND ADDITIONAL INFORMATION</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We have filed with the SEC a registration statement on Form S-1 under the Securities Act, with respect to the securities being offered by this prospectus. This prospectus does not contain all of the information in the registration statement and its exhibits. For further information with respect to us and the securities offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We file electronically with the SEC annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements and other information and amendments to those reports filed or furnished pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934. The SEC maintains an Internet site (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Copies of these reports, proxy and information statements and other information may be obtained by electronic request at the following e-mail address:&nbsp;<u>publicinfo@sec.gov</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We make available, free of charge and through our Internet web site at www.diffusionpharma.com, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to any such reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. We also make available, free of charge and through our Internet web site, to any stockholder who requests, the charters of our board committees, our Corporate Governance Guidelines and our Code of Business Conduct and Ethics. Requests for copies can be directed to Investor Relations at (434) 220-0718. The information set forth on, or connected to, our website is expressly not incorporated by reference into, and does not constitute a part of, this prospectus.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The SEC allows us to incorporate by reference information into this prospectus. This means we can disclose information to you by referring you to another document we filed with the SEC. We will make those documents available to you without charge upon your oral or written request. Requests for those documents should be directed to Investor Relations Department, Diffusion Pharmaceuticals Inc., 1317 Carlton Avenue, Suite 200, Charlottesville, Virginia 22902, Attention: Secretary, telephone: (434) 220-0718. This prospectus incorporates by reference the following documents (other than any portion of the respective filings furnished, rather than filed, under the applicable SEC rules) that we have filed with the SEC but have not included or delivered with this prospectus:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our Annual Report on <a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919005256/dffn20181231_10k.htm" style="-sec-extract:exhibit;">Form 10-K for the fiscal year ended December 31, 2018, filed with the SEC on March 19, 2019</a>;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">31</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our Quarterly Reports on Form 10-Q for the fiscal quarters ended <a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919009285/dffn20190331_10q.htm" style="-sec-extract:exhibit;">March 31, 2019</a>&nbsp;,&nbsp;<a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919016051/dffn20190630_10q.htm" style="-sec-extract:exhibit;">June 30, 2019</a>&nbsp;and <a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919022149/dffn20190930_10q.htm" style="-sec-extract:exhibit;">September 30, 2019</a>, filed with the SEC on May 9, 2019,&nbsp;August 8, 2019&nbsp;and November 8, 2019, respectively;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our Current Reports on Form 8-K filed with the SEC on <a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919001064/dffn20190118_8k.htm" style="-sec-extract:exhibit;">January 18, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919010905/dffn20190525_8k.htm" style="-sec-extract:exhibit;">May 28, 2019</a>&nbsp;and <a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919011940/dffn20190613_8k.htm" style="-sec-extract:exhibit;">June 13, 2019</a>;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our Definitive Proxy Statement on <a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919008328/dffn20190429_def14a.htm" style="-sec-extract:exhibit;">Schedule 14A filed with the SEC on April 30, 2019</a>; and</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the description of our common stock included in our amended registration statement on <a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916041352/dffn20161108_8a12b.htm" style="-sec-extract:exhibit;">Form 8-A filed on November 8, 2016</a> under the Exchange Act, and any amendment or report we may file with the SEC for the purpose of updating such description.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In addition, all documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the termination of the offering shall be deemed to be incorporated by reference into this prospectus (other than current reports or portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">You may request a free copy of any or all of the documents incorporated by reference in this prospectus by writing or telephoning us at the following address:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Diffusion Pharmaceuticals Inc.</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">1317 Carlton Avenue, Suite 200</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Charlottesville, Virginia 22902</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(434) 220-0718</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Attention: Investor Relations</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In accordance with Rule 412 of the Securities Act, any statement contained in a document incorporated by reference herein shall be deemed modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">32</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 0.75pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 0.75pt;text-align:center;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 0.75pt;text-align:center;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 0.75pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 0.75pt;text-align:center;">&nbsp;</p>

<div style="text-align: center;"><img alt="" src="image01.jpg"></div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 0.75pt;text-align:center;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;<br>
&nbsp;<br>
&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>Up to $8,000,000 consisting of</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>12,121,212 Class A Units consisting of Shares of Common Stock and Series I Warrants and Series II Warrants or</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>12,121,212&nbsp;Class B Units consisting of Pre-Funded Warrants and Series I Warrants and Series II Warrants</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>(or some combination of Class A Units and Class B Units)</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>12,121,212&nbsp;Shares of Common Stock underlying the Series I Warrants</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>12,121,212&nbsp;Shares of Common Stock underlying the Series II Warrants</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;<br>
&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><br>
<br>
&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;"><b>PROSPECTUS</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><br>
<br>
&nbsp;<br>
&nbsp;<br>
&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;"><b>H.C. Wainwright &amp; Co.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;<br>
&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>PART II</b><br>
<b>INFORMATION NOT REQUIRED IN PROSPECTUS</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>&nbsp;</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Item 13. Other Expenses of Issuance and Distribution.</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The following table sets forth all costs and expenses, other than Placement Agent&#8217;s fees, paid or payable by us, in connection with the sale of the securities being registered under this registration statement. All amounts shown are estimates except for the SEC registration fee and the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Amount</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">SEC registration fee</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,181.10</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">FINRA filing fee</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,175</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Blue-sky qualification fees and expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,500</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Legal fees and expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">85,000</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accounting fees and expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100,000</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Transfer agent and registrar fees and expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,500</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Miscellaneous expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">138,644.90</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">335,000</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Item 14. Indemnification of Directors and Officers.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We are incorporated under the laws of the State of Delaware. Section&nbsp;145 of the Delaware General Corporation Law (&#8220;DGCL&#8221;), provides that a Delaware corporation may indemnify any persons who are, or are threatened to be made, parties to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person was an officer, director, employee or agent of such corporation, or is or was serving at the request of such person as an officer, director, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation&#8217;s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was illegal. A Delaware corporation may indemnify any persons who are, or are threatened to be made, a party to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person was a director, officer, employee or agent of such corporation, or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit provided such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation&#8217;s best interests except that no indemnification is permitted without judicial approval if the officer or director is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him or her against the expenses which such officer or director has actually and reasonably incurred. Article V of our restated certificate of incorporation provides for indemnification of our directors and officers, and Article X of our amended and restated bylaws provides for indemnification of our directors, officers, employees and other agents, to the maximum extent permitted by the DGCL. We have entered into indemnification agreements with our officers and directors. In addition, we maintain a policy providing directors&#8217; and officers&#8217; liability insurance.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">II-1</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Section&nbsp;102 of the DGCL permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duties as a director, except for liability:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">&#8226;</td>
			<td style="vertical-align:top;">for any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders;</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">for acts related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:22pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">for any transaction from which the director derived an improper personal benefit.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Our restated certificate of incorporation and amended and restated bylaws include such a provision. Expenses incurred by any officer or director in defending any such action, suit or proceeding in advance of its final disposition shall be paid by us upon delivery to us of an undertaking, by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be indemnified by us.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Item 15. Recent Sales of Unregistered Securities.</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Set forth below is information regarding securities issued by us since January 1, 2016 that were not registered under the Securities Act of 1933, as amended, or the Securities Act. Also included is the consideration, if any, received by us, for such securities and information relating to the Securities Act, or rule of the SEC, under which exemption from registration was claimed.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>Acorn Advisory Services</i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On May 21, 2018 and October 22, 2018, we issued 3,031 and 4,762 shares of Common Stock (each as adjusted for the Reverse Stock Split), respectively, to Acorn Management Partners, L.L.C. as consideration for advisory services provided to us. The securities were issued to an accredited investor in reliance upon an exemption pursuant to Section 4(a)(2) of the Securities Act and the rules and regulations promulgated thereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>March 2017 Private Placement</i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In March 2017, we conducted a private placement (the &#8220;Private Placement&#8221;), pursuant to which we issued 12,376,329 shares of Series A Preferred Stock and 5-year warrants to purchase 825,099 shares of our common stock at an exercise price equal to $33.30 per share (the &#8220;Warrants&#8221;). The aggregate gross proceeds from the Private Placement were $25.0 million, prior to deducting placement agent fees and expenses payable by us. Maxim Merchant Capital, a division of Maxim Group LLC (&#8220;Maxim&#8221;), acted as our sole placement agent in the Private Placement. We issued to Maxim and its designees 5-year warrants, to purchase 78,638 shares of common stock at an exercise price equal to $33.30 per share, with such warrants containing a cashless exercise provision. The securities were issued to accredited investors in reliance upon an exemption pursuant to Section 4(a)(2) of the Securities Act and the rules and regulations promulgated thereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">As part of the Private Placement, we entered into registration rights agreements with the investors in the Private Placement and Maxim, pursuant to which we agreed to file a registration statement to register for resale the shares of common stock (i) issued and outstanding as a result of, or issuable upon, the conversion of the shares of Series A Preferred Stock, (ii) issued and outstanding as a result of, or issuable upon, the exercise of the Warrants sold in the Private Placement and (iii) issuable as payment of dividends accruing on the Series A Preferred Stock. Such registration statement was declared effective on June 1, 2017.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On January 22, 2018, substantially concurrently with the completion our January 2018 public offering of common stock and warrants (the &#8220;January Offering&#8221;), all outstanding shares of Series A Preferred Stock mandatorily converted into an equivalent number of shares of our common stock. We were obligated to issue for no consideration to the holders of Series A Preferred Stock as of January 22, 2018 an aggregate of 553,752 shares of common stock upon conversion of the outstanding Series A Preferred Stock, 777,895 shares of common stock pursuant to a make-whole adjustment and an aggregate of 39,596 shares of common stock in respect of accrued but unpaid dividends on the Series A Preferred Stock. The dividend shares also include 7 shares of common stock issuable in respect of accrued but unpaid dividends on shares of Series A Preferred Stock converted into common stock voluntarily by the holder prior to the closing of the January Offering.&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">II-2</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>Warrant Private Placement</i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On May 23, 2019, we entered into a Securities Purchase Agreement with certain institutional and accredited investors (the &#8220;Securities Purchase Agreement&#8221;) providing for the sale in a registered direct offering by the Company of 1,317,060 shares of our common stock, par value $0.001 per share at an offering price of $4.77 for gross proceeds of approximately $6,282,376 before the deduction of the placement agent fee and offering expenses. Concurrently with the closing of the transactions contemplated by the Securities Purchase Agreement, in a private placement transaction, we issued to the investors warrants to purchase an aggregate of 1,317,060 shares of our common stock at an initial exercise price equal to $5.00 per share and to the placement agent warrants to purchase up to 65,853 shares of common stock at an initial exercise price equal to $6.11875 per share. The warrants issued to the investors are exercisable for approximately five and one-half years beginning on the date of their issuance. The warrants issued to the placement agent have a term of approximately five years from the date of issuance and (other than the exercise price noted above) are otherwise substantially similar to the warrants issued to the investors. H.C. Wainwright &amp; Co., LLC served as placement agent for the May 2019 private placement. The securities were issued to accredited investors in reliance upon an exemption pursuant to Section 4(a)(2) of the Securities Act and the rules and regulations promulgated thereunder. We registered the 1,382,913 shares of common stock underlying the investors&#8217; warrants and the placement agent&#8217;s warrants on a registration statement on Form S-1 that was declared effective on October 8, 2019.&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Item 16. Exhibits and Financial Statement Schedules.</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>(a) Exhibits.</i></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">See the Exhibit Index attached to this registration statement, which is incorporated by reference herein.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>(b) Financial Statement Schedules.</i></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">No financial statement schedules are provided because the information called for is not required or is shown either in the financial statements or the notes thereto.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Item 17. Undertakings.</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The undersigned Registrant hereby undertakes:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:21pt;">&nbsp;</td>
			<td style="width:22pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">(1)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">That, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant&#8217;s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:21pt;">&nbsp;</td>
			<td style="width:22pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">(2)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:21pt;">&nbsp;</td>
			<td style="width:22pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">(3)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser (i) any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424 promulgated under the Securities Act, (ii) any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant, (iii) the portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and (iv) any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">II-3</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:21pt;">&nbsp;</td>
			<td style="width:22pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">(4)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:21pt;">&nbsp;</td>
			<td style="width:22pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">(5)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:21pt;">&nbsp;</td>
			<td style="width:22pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">(6)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">II-4</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>EXHIBIT INDEX</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="vertical-align: top; width: 7%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Exhibit<br>
			No.</b></p>

			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="3" style="vertical-align: top; width: 39%; border-bottom: thin solid rgb(0, 0, 0);"><b>Description</b></td>
			<td style="vertical-align: top; width: 1%; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td colspan="4" style="vertical-align: top; width: 53%; border-bottom: thin solid rgb(0, 0, 0);"><b>Method of Filing</b></td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">3.1</td>
			<td colspan="3" style="vertical-align: top; width: 39%;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919005256/ex_137220.htm" style="-sec-extract:exhibit;">Certificate of Incorporation of Diffusion Pharmaceuticals Inc., as amended</a></td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="4" style="vertical-align: top; width: 53%;">Incorporated by reference to Exhibit 3.1 to the registrant&#8217;s annual report on Form 10-K for the year ended December 31, 2018</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="3" style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="4" style="vertical-align: top; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">3.2</td>
			<td colspan="3" style="vertical-align: top; width: 39%;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916028395/ex3-4.htm" style="-sec-extract:exhibit;">Bylaws of Diffusion Pharmaceuticals Inc., as amended</a></td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="4" style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.2pt;margin-top:0pt;text-align:justify;">Incorporated by reference to Exhibit 3.4 to the registrant&#8217;s annual report on Form 10-K for the year ended December 31, 2015</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="3" style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="4" style="vertical-align: top; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">4.1</p>
			</td>
			<td colspan="3" style="vertical-align: top; width: 39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774917004538/ex4-1.htm" style="-sec-extract:exhibit;">Form of Warrant issued to Investors in the 2017 Private Placement by Diffusion Pharmaceuticals Inc.</a></p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="4" style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Exhibit 4.1 to the registrant&#8217;s current report on Form 8-K filed on March 15, 2017</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="3" style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="4" style="vertical-align: top; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">4.2</p>
			</td>
			<td colspan="3" style="vertical-align: top; width: 39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774918000800/ex_103239.htm" style="-sec-extract:exhibit;">Form of 2018 Common Stock Warrant</a></p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="4" style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Exhibit 4.1 to the registrant&#8217;s current report on Form 8-K filed on January 19, 2018</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="3" style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="4" style="vertical-align: top; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">4.3</p>
			</td>
			<td colspan="3" style="vertical-align: top; width: 39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774918000941/ex_103358.htm" style="-sec-extract:exhibit;">Form of 2018 Underwriters&#8217; Warrant</a></p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="4" style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Exhibit 4.2 to the registrant&#8217;s current report on Form 8-K filed on January 22, 2018</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="3" style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="4" style="vertical-align: top; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">4.4</p>
			</td>
			<td colspan="3" style="vertical-align: top; width: 39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919010905/ex_145858.htm" style="-sec-extract:exhibit;">Form of May 2019 Warrant</a></p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="4" style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Exhibit 4.1 to the registrant&#8217;s current report on Form 8-K filed on May 28, 2019</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">II-5</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="vertical-align: top; width: 7%;"> 4.5 </td>
			<td colspan="1" style="vertical-align: top; width: 39%;"> <a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919010905/ex_145859.htm" style="-sec-extract:exhibit;">Form of May 2019 Placement Agent&#8217;s Warrant</a> </td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: bottom; width: 53%;">
			<p style="margin: 0pt;"> Incorporated by reference to Exhibit 4.2 to the registrant&#8217;s current report on Form 8-K filed on May 28, 2019 </p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: bottom; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;"> 4.6 </td>
			<td colspan="1" style="vertical-align: top; width: 39%;"> <a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919022192/ex_163091.htm" style="-sec-extract:exhibit;">Form of Series I Warrant</a> </td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: bottom; width: 53%;"> Incorporated by reference to Exhibit 4.6 to Amendment No. 2 to the registrant&#8217;s Registration Statement on Form S-1 (Registration Number 333-234234), filed with the SEC on November 8, 2019 </td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: bottom; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;"> 4.7 </td>
			<td colspan="1" style="vertical-align: top; width: 39%;"> <a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919022192/ex_163092.htm" style="-sec-extract:exhibit;">Form of Seriees II Warrant</a> </td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: bottom; width: 53%;"> Incorporated by reference to Exhibit 4.7 to Amendment No. 2 to the registrant&#8217;s Registration Statement on Form S-1 (Registration Number 333-234234), filed with the SEC on November 8, 2019 </td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: bottom; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;"> 4.8 </td>
			<td colspan="1" style="vertical-align: top; width: 39%;"> <a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919022192/ex_163093.htm" style="-sec-extract:exhibit;">Form of Pre-Funded Warrant</a> </td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: bottom; width: 53%;"> Incorporated by reference to Exhibit 4.8 to Amendment No. 2 to the registrant&#8217;s Registration Statement on Form S-1 (Registration Number 333-234234), filed with the SEC on November 8, 2019 </td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: bottom; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;"> 4.9 </td>
			<td colspan="1" style="vertical-align: top; width: 39%;"> <a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919022192/ex_163097.htm" style="-sec-extract:exhibit;">Form of Placement Agent&#8217;s Warrant</a> </td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: bottom; width: 53%;"> Incorporated by reference to Exhibit 4.9 to Amendment No. 2 to the registrant&#8217;s Registration Statement on Form S-1 (Registration Number 333-234234), filed with the SEC on November 8, 2019 </td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: bottom; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.2pt;margin-top:0pt;text-align:left;"> 5.1 </p>
			</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.2pt;margin-top:0pt;text-align:left;"> <a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919022192/ex_163175.htm" style="-sec-extract:exhibit;">Opinion of Dechert LLP</a> </p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: bottom; width: 53%;"> Incorporated by reference to Exhibit 5.1 to Amendment No. 2 to the registrant&#8217;s Registration Statement on Form S-1 (Registration Number 333-234234), filed with the SEC on November 8, 2019 </td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: bottom; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> 10.1 </p>
			</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> <a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916038465/ex10-1.htm" style="-sec-extract:exhibit;">Employment Agreement, dated as of September 6, 2016, by and between David G. Kalergis and Diffusion Pharmaceuticals Inc.*</a> </p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> Incorporated by reference to Exhibit 10.1 to the registrant&#8217;s current report on Form 8-K as filed on September 8, 2016 </p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> 10.2 </p>
			</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> <a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774918017551/ex_124640.htm" style="-sec-extract:exhibit;">Amended and Restated Employment Agreement, dated as of September 21, 2018, by and between William Karl Hornung and Diffusion Pharmaceuticals Inc.*</a> </p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed September 27, 2018. </p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> 10.3 </p>
			</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> <a href="http://www.sec.gov/Archives/edgar/data/1053691/000110465915046210/a15-14238_1ex10d2.htm" style="-sec-extract:exhibit;">Diffusion Pharmaceuticals Inc. 2015 Equity Incentive Plan*</a> </p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> Incorporated by reference to Exhibit 10.2 to the registrant&#8217;s current report on Form 8-K as filed on June 18, 2015 </p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> 10.4 </p>
			</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> <a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916033633/dffn20160607_def14a.htm" style="-sec-extract:exhibit;">Amendment No. 1 to Diffusion Pharmaceuticals Inc. 2015 Equity Incentive Plan*</a> </p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> Incorporated by reference to Appendix B to the registrant&#8217;s definitive proxy statement on Schedule 14A filed on June 10, 2016 </p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: bottom; width: 39%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> 10.5 </p>
			</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> <a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774918006050/ex_108103.htm" style="-sec-extract:exhibit;">Form of Diffusion Pharmaceuticals Inc. Stock Option Award Agreement*</a> </p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> Incorporated by reference to Exhibit 10.5 to the registrant&#8217;s annual report on Form 10-K for the year ended December 31, 2017 </p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: bottom; width: 39%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> 10.6 </p>
			</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> <a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916028395/ex10-24.htm" style="-sec-extract:exhibit;">Form of Diffusion Pharmaceuticals LLC Stock Option Award Agreement*</a> </p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> Incorporated by reference to Exhibit 10.24 to the registrant&#8217;s annual report on Form 10-K for the year ended December 31, 2015 </p>
			</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">II-6</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">10.7</p>
			</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000110465915046210/a15-14238_1ex10d3.htm" style="-sec-extract:exhibit;">Form of 2015 Incentive Stock Option Agreement under the Diffusion Pharmaceuticals Inc. 2015 Equity Incentive Plan*</a></p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Exhibit 10.3 to the registrant&#8217;s current report on Form 8-K filed on June 18, 2015</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">10.8</p>
			</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000110465915046210/a15-14238_1ex10d4.htm" style="-sec-extract:exhibit;">Form of 2015 Non-Statutory Stock Option Agreement under the Diffusion Pharmaceuticals Inc. 2015 Equity Incentive Plan*</a></p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Exhibit 10.4 to the registrant&#8217;s current report on Form 8-K filed on June 18, 2015</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">10.9</p>
			</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000110465915025785/a15-2678_1ex10d12.htm" style="-sec-extract:exhibit;">Form of Stock Option Agreement between the Company and certain former Executive Officers*</a></p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Exhibit 10.12 to the registrant&#8217;s annual report on Form 10-K for the fiscal year ended December 31, 2014</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">10.10</p>
			</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000110465915025785/a15-2678_1ex10d13.htm" style="-sec-extract:exhibit;">Form of Stock Option Agreement between the Company and certain former Directors*</a></p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Exhibit 10.13 to the registrant&#8217;s annual report on Form 10-K for the fiscal year ended December 31, 2014</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">10.11</p>
			</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916028395/ex10-3.htm" style="-sec-extract:exhibit;">Form of Indemnification Agreement between Diffusion Pharmaceuticals Inc. and each of its Directors and Officers*</a></p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Exhibit 10.3 to the registrant&#8217;s annual report on Form 10-K for the year ended December 31, 2015</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">10.12</p>
			</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000105369117000015/lease1317carltonaveste400fu.htm" style="-sec-extract:exhibit;">Lease Agreement, dated March 31, 2017, by and between Diffusion Pharmaceuticals Inc. and One Carlton LLC</a></p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Exhibit 10.4 to the registrant&#8217;s quarterly report on Form 10-Q for the quarter ended March 31, 2017</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: bottom; width: 39%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">10.13</p>
			</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916023394/ex10-2.htm" style="-sec-extract:exhibit;">Contingent Value Rights Agreement, dated as of January 8, 2016, by and between Diffusion Pharmaceuticals Inc. and Computershare, Inc., as Rights Agent</a></p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Exhibit 10.2 to the registrant&#8217;s current report on Form 8-K filed on January 8, 2016</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<p style="margin: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">II-7</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="vertical-align: top; width: 7%;"> 10.16 </td>
			<td colspan="1" style="vertical-align: top; width: 39%;"> <a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919022192/ex_163098.htm" style="-sec-extract:exhibit;">Engagement Letter, dated October 7, 2019, by and between Diffusion Pharmaceuticals Inc. and H.C. Wainwright &amp; Co., LLC</a> </td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;"> Incorporated by reference to Exhibit 10.16 to Amendment No. 2 to the registrant&#8217;s Registration Statement on Form S-1 (Registration Number 333-234234), filed with the SEC on November 8, 2019 </td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;"> 10.17 </td>
			<td colspan="1" style="vertical-align: top; width: 39%;"> <a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919022192/ex_163099.htm" style="-sec-extract:exhibit;">Form of Securities Purchase Agreement</a> </td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;"> Incorporated by reference to Exhibit 10.17 to Amendment No. 2 to the registrant&#8217;s Registration Statement on Form S-1 (Registration Number 333-234234), filed with the SEC on November 8, 2019 </td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.2pt;margin-top:0pt;text-align:left;"> 21.1 </p>
			</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.2pt;margin-top:0pt;text-align:left;"> <a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919005256/ex_137086.htm" style="-sec-extract:exhibit;">Subsidiaries of Diffusion Pharmaceuticals Inc.</a> </p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.2pt;margin-top:0pt;text-align:left;"> Incorporated by reference to Exhibit 21.1 to the registrant&#8217;s annual report on Form 10-K for the year ended December 31, 2018 </p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: bottom; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.2pt;margin-top:0pt;text-align:left;"> 23.1 </p>
			</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.2pt;margin-top:0pt;text-align:left;"> <a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919022192/ex_163229.htm" style="-sec-extract:exhibit;">Consent of KPMG LLP, independent registered public accounting firm</a> </p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.2pt;margin-top:0pt;text-align:left;"> Incorporated by reference to Exhibit 23.1 to Amendment No. 2 to the registrant&#8217;s Registration Statement on Form S-1 (Registration Number 333-234234), filed with the SEC on November 8, 2019 </p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.2pt;margin-top:0pt;text-align:left;"> 23.2 </p>
			</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.2pt;margin-top:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919022192/ex_163175.htm" style="-sec-extract:exhibit;"> Consent of Dechert LLP </a></p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.2pt;margin-top:0pt;text-align:left;"> Included in Exhibit 5.1 hereto </p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.2pt;margin-top:0pt;text-align:left;"> 24.1 </p>
			</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.2pt;margin-top:0pt;text-align:left;"> <a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919020753/dffn20191025_s1a.htm#poa" style="-sec-extract:exhibit;">Powers of Attorney</a> </p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.2pt;margin-top:0pt;text-align:left;"> Previously filed. </p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 39%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;"> * </td>
			<td colspan="1" style="vertical-align: top; width: 39%;"> A management contract or compensatory plan or arrangement. </td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 53%;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">II-8</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>SIGNATURES</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> Pursuant to the requirements of the Securities Act, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Charlottesville, Virginia, on the 12<sup>th</sup> day of November, 2019. </p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:49.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Diffusion Pharmaceuticals Inc.</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">By:&nbsp; &nbsp; &nbsp;<u>/s/ David G. Kalergis</u></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-align: justify;">David G. Kalergis</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-align: justify;"><i>Chief Executive Officer (Principal Executive </i></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-align: justify;"><i>Officer)</i></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:30%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> <b>SIGNATURE</b> </p>
			</td>
			<td style="vertical-align:top;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:45.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> <b>TITLE</b> </p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:22.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> <b>DATE</b> </p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:30%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:45.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:22.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:30%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> /s/ David G. Kalergis </p>
			</td>
			<td style="vertical-align:top;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:45.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> Chief Executive Officer and Chairman of the Board </p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:22.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> November 12,&nbsp;2019 </p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:30%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> David G. Kalergis </p>
			</td>
			<td style="vertical-align:top;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:45.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> <i>(Principal Executive Officer)</i> </p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:22.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:30%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:45.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:22.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:30%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> /s/ William K. Hornung </p>
			</td>
			<td style="vertical-align:top;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:45.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> Chief Financial Officer </p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 22.9%; text-align: center;"> November 12,&nbsp;2019 </td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:30%;">&nbsp;</td>
			<td style="vertical-align:top;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:45.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> <i>(Principal Financial </i><i>&amp; Accounting </i><i>Officer)</i> </p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:22.9%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:30%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:45.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:22.9%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:30%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> * </p>
			</td>
			<td style="vertical-align:top;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:45.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> Director </p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 22.9%; text-align: center;"> November 12,&nbsp;2019 </td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:30%;">&nbsp;</td>
			<td style="vertical-align:top;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:45.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:22.9%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:30%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:45.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:22.9%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 30%; text-align: center;"> * </td>
			<td style="vertical-align:top;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:45.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> Director </p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 22.9%; text-align: center;"> November 12,&nbsp;2019 </td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:30%;">&nbsp;</td>
			<td style="vertical-align:top;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:45.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:22.9%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:30%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:45.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:22.9%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 30%; text-align: center;"> * </td>
			<td style="vertical-align:top;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:45.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> Director </p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 22.9%; text-align: center;"> November 12,&nbsp;2019 </td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:30%;">&nbsp;</td>
			<td style="vertical-align:top;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:45.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:22.9%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:30%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:45.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:22.9%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 30%; text-align: center;"> * </td>
			<td style="vertical-align:top;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:45.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> Director </p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 22.9%; text-align: center;"> November 12,&nbsp;2019 </td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:30%;">&nbsp;</td>
			<td style="vertical-align:top;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:45.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:22.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:30%;">&nbsp;</td>
			<td style="vertical-align:top;width:1%;">&nbsp;</td>
			<td style="vertical-align:top;width:45.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:22.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:30%;">&nbsp;</td>
			<td style="vertical-align:top;width:1%;">&nbsp;</td>
			<td style="vertical-align:top;width:45.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:22.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 30%; border-bottom: thin solid rgb(0, 0, 0);"> By: &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; /s/ David G. Kalergis </td>
			<td style="vertical-align:top;width:1%;">&nbsp;</td>
			<td style="vertical-align:top;width:45.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:22.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 30%; text-indent: 36pt;"> &nbsp;&nbsp; &nbsp;&nbsp; David G. Kalergis </td>
			<td style="vertical-align:top;width:1%;">&nbsp;</td>
			<td style="vertical-align:top;width:45.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:22.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 30%; text-indent: 36pt;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Attorney-In-Fact </td>
			<td style="vertical-align:top;width:1%;">&nbsp;</td>
			<td style="vertical-align:top;width:45.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:22.9%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;">II-9</p>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>dffn20191014_s1img002.jpg
<TEXT>
begin 644 dffn20191014_s1img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %0 E$# 2(  A$! Q$!_\0
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BC-&1ZT %%%% !1110 4444
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MO]JSPY\/+>2W_L&^L_,FC:,%V<ACNW=1C KW6OE;QG_R?SX/_P"O%?\ T%Z
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MZE%7.W'KZT ?1$'B[PO=:!<>(+?Q#I\NDVQ99KU+E#%&1P06!P*R/^%K?#,
M'_A/M! 8X!^WQ\_^/5X)\+[[P_X0^+LO@.'0M1LO"'BJRC%M!K5BT"M>Q)B0
M!7&"' S]370>$O"_AF;]K+Q]ILOA[37LH-)M6CMVMD*(Q89(7& : /?;77-(
MO]2FTVRU2UN;R"-)I((Y59TC<95B <@'L>]9-W\0O FGZQ_8][XQT:WU -L-
MO)>QJX/H1G@^U>!7+:K:?&GXXR>'%*ZG%X<A^RK$O.\)Q@?RKH/ACH'PHNOV
M:;2\O[/2;BUFL6DU6[NMAE\[DN9'/S!@>G?I0![EJ6NZ+H\-K+JNJVEC%=R+
M# ]Q,J"5VZ*I)Y)]!4E]JVF:;+:1:A?V]H]Y,+>W6:0*9I#R$7/4^PKXJGL+
MKQ/\ ?A3HGB&6Z^Q7WBE[.UF?B7[(0XC8$^G;Z5T&M^(-?M_&_PY^%_C0/+K
M_A[Q/!):WY4[-1LMK+'-G^^. ?>@#ZAUOQQX.\-WD=GX@\4:9I=S(,K#<W21
MN1ZX)SBMZ"XM[JVCN;:>.>"50R21L&5QZ@C@BOFFZ\/WUS\2_'^M> K[PSXG
M,LXBUG1O$ENR2VS*F,1R]=A'3M7H?P"U;1=6^#]FV@Z+-HMI:W,UL;.2Y,ZI
M(K9;9(?O)D\4 >L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 E%%% "T444 %%&:,B@ HHHH **,CUHS0 449'K1D4 %%%&: "BBB@ HHH
MH 0C*D=<^M<_X9\&^&O!MK=V_AG1X=-BO)C<3K#D;Y#W-=#10!BV'AO1-,U_
M4M>L=,A@U/4]GVRY5?FFVC"Y^E5+[P1X5U/5K_5;[0[>:]U"R_L^ZF9?FF@_
MN-Z_SKI<BB@#G[CPCX;N_!H\'7.BV\N@B%;86)7]V(QT ],8JOK7@'P?XBT.
MTT/6_#UI?6-FH2V25,F  8^1NJ\ =#7444 <CX9^'/@GP;/)<^&_#=I87,B[
M7N I>4CTWMDX]LUC3? _X43SRS2>!]/WRL7<A2,DG). ?6O1Z* .?E\(>'+C
MP=_PA\^CPMH/DBW^Q$9C\L'(7\P#4^H^&=#U;PR?#6I:7!=:.8UA-I(N4V+C
M:,>V!6S10!Y[9_!;X7V%];WUIX-LH;FWD66.1=V48'((Y[8J75/@_P##76]9
MN=8U7P?875_=/YD\SH<RMZMZUWM% &?I>D:9HFF0Z7H^GP6%E"-L<%N@1$'T
M%9WB7P=X;\7BP3Q)I$.HK83BYMQ*/]7(.]=#10 W'3C@5CZEX9T/5]8TO6-2
MTV*YO])=I+*9Q\T#,,$C\*VLT4 8=YX7T&_\2Z?XDO-+BFU?3E9+6[(_>1*W
M49[CVK-7X<^"ET+^PU\.VPTW[=_:7D;3M^T;MWF?7-==10!RLW@'PA<:AKFH
M2^'K5KK7H1;ZC)MYN8Q_"U6-.\&^&=)UF+6=.T6WM[^*S33XYU7YDMT^[&/0
M5T5% &'?>%]!U'Q%:^(+W2XIM4M8)+6*Y899(I!AU^AINF>$O#NC>%V\+Z=I
M%O!HI5T:S"9C8/\ >!'?.36]10!S+>!/";^"$\%2:) _A^-0BV39* !MP'KU
MKH(8D@@C@AC$<<:A$4<  < ?E4U1LYW;57<: ).U<Y<>"_#-YXQL_&%UHL$N
MO6<1AAO&'SHI_3N>>V:WT<,#Q@C@U)D4 8^F^'-%TC5M4U73=-BMKW5I%FO9
MD'S3N!@$_A65!\//!=II^MZ?;>&;..TUYS)J,(3Y+ECW85UM% '!:3\'_AGH
M>I0ZEI?@O3H;N YBE,6XQGU&<X/N*Z.3PUH<WBN'Q5)I<1UJ"!K6.\(^=8V.
M2M;5% '!:W\(?AOXBU>35M8\(6-S>R$-)(%*^<1_?"D!OQS6X?!OA@ZAHVH?
MV':I<Z*C1Z>RQA1;*PP0@' KH:* ,;6/#6A^(+K3;K6--BO)M+N!=6CN.89.
MFY32VWAK1+/Q/>^)K;38HM7OHD@N+H#YI$7[JFMC(HH Q;7PSH=EXDU#Q%::
M9%%JVH1I%=72K\TJK]T&N7OO@Q\+]2UB35KSP7ITES*_F280JDC>K(/E)_"O
M0LBB@#"U'PKX?U9-+CU'2+>=-)G6YL5V8%O(HPI4#I@<4W5_"/AO7M8TO6-8
MT>WO-0TJ3S;*XD3YX&]C]>U;^:* .)\1?"OP!XKU5M6U[PO:7=\RA7G */*!
MT#%<;A]:Z;2])TW0]-@TS1].AL;*!=L<$"!$0>P%:&11F@ HHR/6B@ HHHH
M**,BB@ HHHH **** "BC-% !1110 4444 %%%% "4444 ?*S?M$>-=Q_XENE
M=?[C_P#Q5)_PT/XU_P"@;I7_ 'P__P 57CYZGZFBO#]O4[GZI_9.#_Y]H]IL
M_CO\0[]Y5T_0+&Z,:[W$,,C[5]3@\"J__#0WC7&?[-TK_OE__BJ@^!Y']I>*
M<X'_ !*S_,U6T_X?:/JO@'0KZR>4:]=J;IX#)Q<0I)MD5!V8*01CWK9.JXW4
MCR*E/ 4JTJ=2DK*QH?\ #0_C7_H&Z7_WP_\ \52?\-$>-/\ H&Z5_P!\O_\
M%52U?PIX3\/:7XIU*XTN>]BTO4H[."$W31 (R*QY'?)-31?#_P .S;]1B^U"
MQN?#\VK6]M-(1);RIC@D?>7FB];N/ERU*[IZ>A/_ ,-#^-<G_B6Z7]-C_P#Q
M5'_#0_C3K_9VE_\ ?#__ !5<WK&D>$_!]CI5GJVFWFL:E?V27;S)=>1%%NZ*
M@'WL5K^$/AQ9ZYX&&H7EI>-J.I"X-A-#GRX=@^7>.AW'/6DI5F[7+=/+HT_:
M2I:-V+O_  T-XTW$_P!FZ5G_ ''_ /BJ7_AHCQH"?^);I6?]Q_\ XJL.UT_P
M6?AE>>)[GPU>F[LKM+&2(7[*'<KDOTXY[5I-\/\ P^L]I>2?:5TZ#P^NL74$
M4F9)G)(VJ?X1\O)IIUGU)<,N5^:EY%K_ (:'\:YQ_9NEY]-C_P#Q5)_PT/XT
M/_,-TK_OE_\ XJLC3/"WACQ-HVE:]IEG<Z=;OJ\>G75E+<&4.K\[D?J#ZUJZ
MK\-M#MSXCU*P:>?2;6SE>U!D.^WN8VVR1OZ]B/8T7K=Q<N6IJ,J=F/\ ^&A_
M&O\ T#=+_P"^7_\ BJ3_ (:&\:_] W2_^^7_ /BJ\>4Y4'V!I:Q]O4[GK?V5
M@_\ GVCTS7_VF/'>DZ0UY;Z7I#N)%7#I)CG/^U7*?\-?_$K_ * F@?\ ?N7_
M .+KSSQE_P BTW_79/ZUYS7I89N4+R9\/G-"G0Q')35E8^B?^&O_ (D_] 30
M/^_<O_Q=;6E_M(_'77;7[7H?P]M=3MMQ7SK2QN)$R.HR&ZU\N?A7U1\/P6_8
MZV_\)Y_PA"_VXY_M7#_+^\.5&SYLG^E=1XACW?[6?Q5T^]>RU'PQI%E=1_?@
MN+>:-U_ L#4'_#7_ ,2N/^)'H'/_ $SE_P#BZW]4O/ /QK^*^EZ)')-XA@\/
M^';F2?4V8V9U&XCV[=S<$)UR3C[U95G\'O LWQ'T?1[S3KFT^V>'+C6+O3!J
M1:&&1"-FRZ'5",YZ@>M %7_AL#XD_P#0$T#_ +]R_P#Q='_#8'Q)_P"@)H'_
M '[E_P#BZQ8_A_X+N-3\4:]=6C6WA[PMIL-U<6&CZP-0>[DD8A0)\84#OQQ6
M'HNC^ O&6@>.]<TCP]=Z)'H&BI=6\#:BUP!.9=NXL0"1MQ\IXS0!VW_#7_Q*
M_P"@'H/_ '[E_P#BZ/\ AL#XD_\ 0$T#_OW+_P#%UQ'@/P/X?\2?#3^W]0CF
M>]/BBQT@LDQ"^1*!O&,XSSUKN?%'P4\)Z>?&>N:')=W?AW3M,N&M,S$O9W\#
MA)(I#U88Y&>H/>@!O_#8'Q)_Z F@?]^Y?_BZ/^&P/B3_ - 30/\ OW+_ /%U
M4U?X3^"]%U'Q#KE\FH2^'O#VB6%_)8VTW[ZZGG4'&\@[$!/4"N6\"^&?"GQ*
M^)ACTCPSJ&G>'=/T^6_O["&]:YEE*+PJ/C.7. !0!VG_  U_\2?^@'H'_?N7
M_P"+H_X; ^)/_0$T#_OW+_\ %U3D^#N@V?QHUSP[=VM['H?_  C<VNZ:DDC)
M+&5C!"N>I*L2"#UQ7S_$WF0JP()([4 ?1G_#7_Q)_P"@)H'_ '[E_P#BZ/\
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M;#4HTY-1.C#3E*M",GHVCL_^%]>,,Y^P:;_WP_\ C2_\+Z\88_X\-._[Y?\
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M%Y,NZ ME?;(XI]OXF\26IT3[.\D;:(6-D4@(V;CE@>.0>^:^X_L5K_SZP_\
M?L4?8[7_ )]8?^_8JOJC2MS'-+/82?-*BFSXK7QWXKWZ@\L,%T-1G6YN%FL0
MZM*H # $<=*KGQCXL;4[W49KB66XO+1K&0M;_*L)ZHJXPH^E?;AL[4#BUB_[
M]BC[':G_ )=8?^_8JOJTOYB5G5-?\N$?$MOXR\30:1#I,L<=[:P*4A%Y9B9H
M1Z*Q&<8J(>+?%2W>DW$4\UN=(C$-HD4)5$4>J@8;\:^W_L=KG_CTB_[]BD^Q
MVN<?9(?^_8I?57_,#SNF_P#ERCX9NM?UV\TK4-+FCQ::A=&]N$CM]H,O3(XX
M'M5N/QEXNBU*QU&*:2.XLK4646+?Y6A'\#KC##ZU]N"SM1_RZQ?]^Q1]CM,_
M\>L/_?L4?57_ ##>>0:LZ*/B.X\8>)[JXL).((]/F^T6\%O:^7$L@YWE0,$\
M]Z;%XN\50VVMVT<TGDZX[27D9M\J[M]XJ,?+G^E?;WV.U_Y]8?\ OV*7[':_
M\^L/_?L4OJLOY@6>4U_RY1^?P@F P+:;'3_5M2^3/_S[R_\ ?MO\*_0#[':_
M\^T/_?L4ALK7'_'K#_W[%3]2\SH_UEE_S[_$_-_QE#<-X:8+;3$^:G B8^OM
M7G7V:[_Y\[G_ +\M_A7ZRBRM/^?6+_O@4?8[3_GTB_[]BNNE3]G&USP<?CGC
M*OM'&Q^37V>Z_P"?.X_[\M_A71?\)=XL'PY/P_$;_P!@-<_;##]C)?S,YSOQ
MG&>U?J)]CM/^?6'_ +]C_"C[':?\^L/_ '['^%;'G'Y9^&_$'B/PGJ%S?Z)#
M+%/=6DEE+YEJ9%:*08<8(XXK>T?XG>/M"CTA;'8PT>RETVU\_3_,Q;RD%XVR
MOSKD<9Z5^EWV.T_Y]8?^_8H^QVG_ #ZP_P#?L4 ?F?;_ !+\=6/B1?$&EV]M
MI5T+<VLD-GI2QV\\1.2LL07:_4\D9JQ:?%3QQI^K7NI6.EZ9:->VJV5Q;QZ*
M@@DB#%AF/;CJ>O7I7Z4?8[3_ )]8?^_8H^QVG_/K#_W[% 'YFM\1O&WDRV\-
MI!:6\U_;ZFT%MI@C19X1B,A0, <#('!IJ?$;Q^EMXJMOM$QM_%;-)JD)LR5D
M=NI08^0X]/05^FALK7M;0C_MF*/L=IC_ (]8?^_8_P * /S2B^*7Q&M_%)\2
M0W#B]>SCTZ5#8[H+B!%PJ21D8;CN:AG^(WC22'5X;.T@TM-8MTM;H:=I@MLQ
MHVX*I105YZD<FOTS^QVG_/K#_P!^Q1]CM/\ GUA_[]B@#\U=.^*OQ$TR;29X
M)/.FTFQETZWDN;#SF-O(06C<L/G''>N9\1:SJ_B?4EU#4-*AMYEC$02QT_[/
M&5!Z[%4#-?JA]CM/^?6'_OV*/L=I_P ^L/\ W[% 'Y,?9[K_ )\[G_ORW^%'
MV>Z_Y\[G_ORW^%?K1]CM/^?6'_O@4?8[3'_'K#_WP/\ "@+GP?\ #F*8> +%
M6MY5(>3AHV!^]]*ZSRIO^>$G_?!KZMT?4+?4AJ %C'$+.]EM,*H.[9CYO;.:
MUQ#;L,^3'_WR*].&8.,5'EV.*6&YFY7/CORIO^>$O_?LU?TG4M4T/58M3TY7
M2YB!"L\18#/!XKZV,-N.L,8^JBD:*W7'[E.?]D54LQYE9Q$L+;J?']PUS=W<
MUS/'(99W+R%8RH)/M6M_PD6O'7H==Y^W0P"W1Q!QL VXQCDX[U]5"&$G'V=
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M',.5641/#7W9\=>5-_SPD_[X-'E3?\\)/^^#7V-]G@_YXI_WR*/L\'_/%/\
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M2A%1C15EYGPQY%Q_S[R_]^S1Y$__ #[R_P#?LU]S_8;3_GUB_P"^!1]AM/\
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M?^>"?]\BA880P80H".X442S&4HN/*)85)WN24445Y1VBT444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 44A957+$ >M 93T- "T444 %%%%
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MO\*7U^/8?^JM?^=?B?6C74+*/GR/UI?M=OGAP!7R2WBSQ23N_P"$[VCV9O\
M"D_X2SQ3W\>?^/-_A5?7X]@_U5K_ //Q?B?7'VJ'&=XYH^V0?WZ^09_&7BR'
M:T?B^6Z)/(C<Y'YBH'\=^,2WR^(+P?1JAYE!=#5<(8F6JFOQ/KVW73[/SQ;1
MI%YTIFDVC[SMR6/UJ<W<.X?.".]?'2^-/$\,;"W\07@+R&1CNR2QZ_Y[4?\
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M,EY_WU1_:5/L'^IN*_GC^)]C?;(?[XH^V0_WQ7QS_P )WXR_Z&2\_P"^J/\
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MLU*VLH-1M+MIR%$D#%E0],'C)_"N@;QJJBWBATV2>WCCEMYC=S;YIHG !3>
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MC\L]#QTH)E*VA /N]<4W#$[5Y-*R,HW,.#TIY=-BF,8<4 D,VMNV]&I70QL
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M5'TU-[P'\/\ 5/&NH!E#6VE1MB:Z(Z_[*>I]^@KZ;TO2M)\*Z1#I>CVHAC4
M!5'S.W<D]R?6M*SLK/3--AL].A2&WB4!(XQ@"ELH8V)N6^:7)'/\/M7T^'PT
M**[L_%,WSFMF-1\VD5L@L[-_,^TW?S2GHO9/_KUY_K=_K'C3Q=<^$M"OSIVF
M6 ']H7<9_>,3_ O\J]"U;4H-'TBYU*ZW&&W0NP12Q/L!7RW!XFU2Q\376O:7
M,;.XN)'<J?G&UCG:0>N*]G"474O)?(^8K5.6R/=+;X2^#((Q]HLYKV3J9;B9
MF)_6L?6? EUX5M9M>\#ZG<VDMJ#*]E+(9(I4 Y4 _P J3PI\6]-N[>.T\2M]
MCO%7YKG;^ZE.>P'3C%;/BGXCZ#I&AR-8WD=[>3QLMO$H+ OTPWIR:.6O&7+)
M7_(+TVKK0V_#NK6OB_PG9ZL(]C2KAE'6-P<-@_7I5U99[%_)NOFC)^63M^/O
M6'\-=(NM%\"6=O?(8[B9FN&0C[FXY _+%=A(L;QE9 "IZ@URS24FH[7-HMM*
MYF20/$?M%CRIY:(=_I5RUO(YTX;D=CU%0Z?QN5&)CW'83W%9^LW$.GSP3(X6
M25L,@_B'K619T-%4[&Z%Q"&JY5"$HHHH ^#6SDXZY-=A8W+*VCS6>HVUOI-O
M$JWL+N!EL_O-R$98L.AKE(?LAF87<DZIC@Q*"?UJR4T(G/GZA^,29KX^"<>A
M^_8OV=1J+E^ITMG8Z%>WD<%G80.JZ=+=,9)2,2 G:CGL ,9I&GT6PTJ[C^RV
M<LLZVK36HE+1JX9M^T^RX/U-<ZK:/'NV7FI+N!5ML:C<#U!]>U-VZ#@8GU 8
MX&(DK6[['GNC%M)U'9'22Z9X<73]699[>3:9VM9!)\Z%3\BGUR*S]931/LNH
M)I\,$+VLT2PR)(6,RLI+9!]"!65MT+/^OO\ _OTE*%T,'_CXU#_OVE+7L:PA
M&,N9U&SJ_M1C?2[B;4;?^Q8].2.XMFE5B[;""FSKNSCFLV:TT6YM[BRL([>*
MZ2QADBEDF(\R4X,@8GC(':L4)H2G=Y]^#Z^4E+Y>@L-IGU _]LTHU[$*C"+T
MFUZ'7VNBZ'-JJV]C!:WT1NQ%.TDK?NX]BG,9'7YMV?I6+H[7$>E:U!I]Y':W
M1EB\IC*(R5#-G!/MBJ,5UIUNCQ6^I:M#&_WE15&[WJ!H_#YX^T7[<8_U24:]
M$2J6K4YMHZM8_#E],SW4D-WJ,$4,<^'"),P'[QU)P"W09_&H+>VT%#IEU$8K
M3]^ROYDH:5UVOALC@#H"".M<WLT(C:9]0(]/*2C;H743:AD_],DH][L5[&"V
MJ2.GBT?27TI[A+6 VD5O%(MT9&\XN9%#A@> ,$X]J@6U\/7=U(L"V=M]GO7B
MB5I"5N80F03GOG@&L5KK3WM5M7U+5&MUQMC*KM'H,5!LT/'_ !\7^/\ KFE/
MY$0I;WJ/R.KF3P_;QW=K8Q66P7=I-O:7YXHR!YFT^Q[57GM= D-W,IMI;4M<
M--<M.?/C<$^6(U[C[OUR:YW9H.,>=?X_ZY)1MT+(;S[_ ".G[I*+OL-48+_E
MX[FKJB:&;:_ALX88GM5@:"57):9F'[Q3]*YRKVW0^UQ?\?\ 3-*3;H?_ #\:
MA_W[6LW%OH=]"K"DFG)N_<I45>VZ'_S\ZA_W[2E$>B'_ )>-0/\ VR6HY&='
MUNF5(]N?FZ4TD9)7I6B?[!8A/M&H _\ 7-:)(]"0C%S?G_MFM'(^QFL53;N9
MY9I,*3Q1(FP@!@:O>7H.S=]KO\^GEK3=NACK/J'_ 'Z6CV;*^LT^A0P3Q3MK
M+U4UK0KH0!_TB_)_ZYI3Y/[#V'_2+_'_ %S2ERLCZ[ QD^^O3K3V'[W)QCVJ
MZJ:"AWF>_/MY2\4Z230F&U;B_P#^_:4<D@>*@WH0*!M'I4$Q7=\IJUG0\?\
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M,PO^$9TG_GPM_P#OTO\ A2_\(SI7_/A;_P#?I?\ "MRBCV<>P>WJ_P S,/\
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M^?"W_P"_2_X4?\(SI7_/A;_]^E_PK<_&C\11[./8/;U?YF8?_",Z5_SX6_\
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MY:/,T#_GSU#_ +_+3^OU?(C_ %7P/:9]#?\ "\/"'_/Q<_\ ?@T?\+P\(?\
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M\7/_ 'X-'_"\/"'_ #\7/_?@U\S44?VA5\@_U0P/G]Y],_\ "\/"'_/Q<_\
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M04444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HHHH
M^#F^\?J:3\*])A^$7C.WN&:73M.N1R-DLQQ^E6O^%8>+,?\ (MZ'_P!_6_QK
MY186KV9^YSSW!7]V:?S1Y6JJN=J@?A0%49VJ!GT%>I_\*P\6?]"WHG_?UO\
M&C_A6'BS_H6]#_[^M_C3^JU>S,_[=P?\R^]'EFU?04%5.#M4GW%>I_\ "L/%
MG_0MZ'_W];_&C_A6'BS_ *%O0_\ OZW^-'U6KV8?V]@_YE]Z/+-H/) S05!8
M,5!(KU/_ (5CXL_Z%O1/^_K?XT?\*P\6?]"WHG_?UO\ &CZK4[,?]NX+^9?>
MCRS:O]T<4*JJ,* ._%>I_P#"L?%G_0MZ)_W];_&C_A6'BS_H6]$_[^M_C1]5
MJ=G]P?V[@OYE]Z/+:*]2_P"%8^+/^A;T3_OZW^-'_"L/%G_0MZ)_W];_ !H^
MJU.S^X?]O8/^9?>CRVBO4O\ A6/BS_H6]$_[^M_C1_PK#Q9_T+>B?]_6_P :
M/JM3L_N#^WL'_,OO1Y;17J7_  K'Q9_T+>B?]_6_QH_X5?XL_P"A<T3_ +^M
M_C1]5J=G]P?V]@_YE]Z/+:*]2_X5AXL_Z%O1/^_K?XT?\*O\6?\ 0N:)_P!_
M6_QH^JU.S#^WL'_,OO1YE'&'4MG!%*&9H2NW..XKTO\ X5GXI'WO#FB_A*W^
M-2CX9^*!&VWP_HJY[>8W/ZT?5:G9F7]NX/\ F7WH\LC8#Y6)VTWN<5ZC_P *
MQ\68_P"1;T3_ +^M_C1_PK'Q7_T+FB?]_6_QH^JU.S+_ +=P?\R^]'F.3*Z@
M  ].*:RLI(;J*]0'PO\ %FX?\4[H@_[:M_C3E^&/BK?\WAO12OJ)6_QH^JU.
MS%_;V$7VE]Z/+651C82?7VIM>J/\,_%3'</#>B8/',C?XTW_ (5AXL_Z%K0_
M^_K?XT?5:G9C6?82WQ+[T>6T5Z7=?"?QA<(JQZ3I=JP.289CD_G57_A3OC;_
M )XV?_?X5/U:K_*S>.=X%J\JB7S//J*]!_X4]XV_YXVG_?\ I/\ A3WC;_GA
M:?\ ?\4OJU;^5E_VS@/^?L?O//Z*[>R^%OB[4/M7V>&U)M;A[:0M+CYU^\*L
M_P#"GO&W_/"T_P"_XH^K5OY6']LX#_G['[SS^BO0?^%/>-O^>-I_W_H_X4]X
MV_YXVG_?^CZO6_E8?VS@/^?L?O//J*]!_P"%/>-O^>-I_P!_Z/\ A3WC;_GC
M:?\ ?^CZO6_E8?VS@/\ G['[SSZBO0?^%/>-O^>-I_W_ */^%/>-O^>-I_W_
M */J];^5A_;. _Y^Q^\\^HKT#_A3WC;_ )X6G_?\4O\ PI[QM_SQM/\ O_1]
M6K?RL/[9P'_/V/WGGW6O1_AW\6K[PG+%I.N,]YH9. _WGM1[?WE]NHJ#_A3W
MC;_GA9_]_A2-\'/&K?\ +&T_[_"MJ-/$4I<T4SS<?BLKQU)TZM2+^>WH?2UO
M<6^I6L6KZ-=)/%(H9'C;*R U>M[R.[1X77;)C#QGTKP/P/X?^)G@#4/W,-O=
MZ1*V9[(W'3U9/[I_0U[@1;ZE;)>VC%),<E>&7VQ7T%.HY1O)69^38W#0H57&
M$U*/1H\+\3> ?$6AW=S'9V4^HZ-/-YR&WY*\]&7VSCTK!FT#7&T>]OCI-U:6
MEFOFO)*NPL<XQ^%?3-M>8D6UNSLE'W7/ ?\ ^O5RXMH+RVDMKJ)9X)05='&0
MP]*]:..FDDU<\=X>+=[F?X8OTU+PKIE[&^Y9+=,G.>0,']16N6ZYZ5!;V]M9
M6R6]K"D$$8PJ(N%45G37#ZA<FU@;; /O..K^PK@D[MV.E*V@LUW]LF^RV;].
M&D!Z>PJ*]O-.\/V?GW#DL>$C!Y=O;_&H-7U'3]!L<;%>Z*GRXEX)]SZ"N*MH
M-0U^_%[?N9)#V'11Z#T%189*UQJ7B'5%N;G*H#^[B!^5!_4UWVCVI@@"L>:A
MTO1XK:)25YK92-4QCZ?2F,DHHHJA!1110 4444 %%%% !1110 4444 %%%%
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M'QD=".XJ6C<".-6 .>,]AVJ2BBF 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 E%%% !17@3_'Z/<VWP_.!_UU7UIG_"_4_P"@!/\ ]_EK
MC^N4>Y]#_J[F/_/L^@,T9KP#_A?J?] "?_O\M'_"_4_Z $__ '^6E]<H]Q?Z
MNYC_ ,^SW_-&:\ _X7['_P! "?\ [_+2?\+]3_H7Y_\ O\M'UVCW#_5W,?\
MGV?0&:,U\_\ _"_4_P"A?G_[_+1_POU/^A?G_P"_RT?7*/</]7<P_P"?9[_1
M7S\?CX/X?#\OXSK1_P +^;_H7Y?^_P */KE'N5_J[F/_ #[/H'\:/QKY]_X7
M\W_0OR_]_A2_\+^;_H7Y?^_PH^N4>XO]7<Q_Y]GT#^-'XU\_?\+^;_H7Y?\
MO\*/^%_'_H7Y?^_PH^N4>X?ZNYC_ ,^_Q/H'\:/QKY^_X7\W_0OR_P#?X4?\
M+];_ *%^7_O\*/KM'N'^KN8_\^_Q/H'_ (%1G_:KY^_X7X?^@!+_ -_A2?\
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M?_4"_P# =O\ &OH[8O\ =HV+_=H^I4@_UCQO<^<?^%2>*_\ J!?^ [?XT?\
M"I/%?_4"_P# =O\ &OH[:O\ =HV+_=I?4J8?ZQXWN?./_"I/%?\ U O_  ';
M_&C_ (5)XK_Z@7_@.W^-?1VQ?[M&Q?[M/ZE2#_6/&]SYQ_X5)XK_ .H%_P"
M[?XT?\*D\5_]0+_P';_&OH[:O]VC8O\ =I?4J8?ZQXWN?./_  J3Q7_U O\
MP';_ !H_X5'XK_Z@7_@.W^-?1VQ?[M&Q?[M/ZE2#_6/&]SYP;X1^*RI&=#'T
MMV!JA_PI#Q/G/V^Q_#=@?I7T]L3^[1L3^[1]1I/H7'B;'1V9\P?\*/\ $_\
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M!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4=1110!6:%]QVL2N,=<8I_D94 NV
M?7-344 5_L_S;BV32K;@+AF)^G%3T4K 0_9U_O'KF@01_P 7S#IS4U%%@(O)
MC_N_K31;H#D$_P!:GHHL @]NE+113 **** "BBB@ HHHH **** "BBB@ HHH
0H **** "BBB@!**** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>dffn20191014_s1img003.gif
<TEXT>
begin 644 dffn20191014_s1img003.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M^O#QK]?_?O_]__D!F!51_17('H$(GI>@>P22M)Z!_#EH53T+0E6A?U8]",V
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ML3A@FX/M63D^ZG0?.%!!&!K7.$D<0 ;T4 8,#&!PIP[3Q\0F!CV2$0#R3AL
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MMUTFX0NEIAC3I4F[ADI<\'W[H EA('_>QBA;X&VEP4B-\W:D00]BT'",D08
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M0?G01$R4$S#Y)%E>I%YZ0#(K8*WQ@C*)'JTD]:@ ><TWZ..=]^CD-3PJD"3
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M&IKLSF<]3W'/?!^Y(DEF A*,2/(JF> "73*$H:S_A&ABNZID*#,#5'R]+2Z
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MTB4ON3+T?9EA2L.LJ?!&:DQ#ZJN"0[$JFF'"W-&.G(<.*W F1I6B6(]A,*Z
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M\;"((Q"$)89A$8>"*OY-*#:K*=[3U%HBQ":)DL@,FBXC0C /\^B'IZ0"\])
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M=ECB1%SP>KCQ-*&"-?$S$V#Q+Z&R#\1P-1#X#FZ0+;67:1N8:2LA!@<  RN
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M1VER&6 @KJ,*KD:C)=S3;4ZJ%JD8/%ZDK#-345N ";Z*&T%DK__YJJ_[RJ\
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MX(DV2XNFB/3Z*H06Z 5FA6)IUHOT%J?(FTCE6VFPS-J>QO2L!5-:6G+L+]
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MS'HXMO^7F$9%6Q>/>5M+.E?K65A(,&R5E+.%AU BTU^2C'-W'$*0[%?\47
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ML<$(4H$FDF (6E (A&"!(UH -U3@(XLH!I+@5KF&27#S-H$1&(FX!7HH!HR
M!IJ()IV(AYK(B7[HAZ'XAYHH%8#XB6@RBIW8B:PH":[HB:28BIT8B+,8BZQH
MAWWHB:O8BZR(A[D8C*+HB:A8BZP(B)L8BZUXB[?HB,K(C+W8BM)HA[Q8C=%(
+C-5(BM4H"0$! #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>dffn20191014_s1img004.gif
<TEXT>
begin 644 dffn20191014_s1img004.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M^O#QK]?_?O_]__D!F!51_17('H$(GI>@>P22M)Z!_#EH53T+0E6A?U8]",V
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M,91!##' ( !U*PG']I&) ,"@?&O+6T%"]10D/K" R] 'X]9X.<LU)AJ4@Z1
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MN>7G;N[S1N]D%CF9L*8G+NLNK>K[<E/$WNX/[M)99@N IF*\A%I9+MK03N\
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M3'#7E)/7TM7G]:HR9?42,[VJCVEGQ,!&UWT$*4//,BB%M59I7@DU6G/TX
M:9,)56!N4$&37X9B+3@>0?MUQ1: -PD81D&^L3;5583=!$T,6RR#A@ILC28&
M,6X$P!I!&"Z8R4W*Q+#"1Z.M19Y7!HY8TSZ2 ("&)F'\MD]7#.[C6W1%*5@>
MEUV"!Z*7^\3_<,!--P @U0V[)4=,##>L,(DD<+VV8P"21+-/([M=ML]?Z,$
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M=V["6;!V,XE&&  VIZ*T,@2]&Q6<)1.3GIR0"-C/BT*+()NZ\XH/$("GN.D
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M0SW<R79J)T[<A'52IWEL9VX,1'>2YXOH1'6B)Y6HIWE<9W7"9T]<)PSE!DZ
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MIN+ J_[A 8QL -#-CM IE50KG9[5$KJ'$;8&7C3GMNZ-@," MQZ  :B OZ@
M;0!  )P9 )S9F87MUP9  '3:UW+MU@+ QR8;V&*M"J1M;7AM9<C:D,@: AP
MW]XKTFI@=<A:N*8MWX(MX%(+QV(MWZ+KXJ+'"LB:UU(+JVY!L>HJK5KNKS8
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M!.ZS79>>@HDED]#0Z:F50OJD$?MVRJ01^>(^6U)E\NW;[[\!]UNE?.U=B?#
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M&9[N*$IHR$%K+:"#'G-F,1O*&9[0AA'/TIFJ':]P12ILH3"!* ,-3[/JTVX
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MUF*+K;GA4#<=4HO_+%TZTUT.=,[E*DX99Y&@@U2%E0I>:2"%0KU.($PG%2G
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M8F,0 ]-\XA6E'$ M!V#!#1#8I@;,L"S#<DUY_[2D'+\H,%:"@Q2L8K"%M.#
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M 96#$H,+,H@5KJP$*^7X<$IH4M-3,+.TY"  /FF*BUL,XY8PR)0M7)B5I7"
M/:"2IUF "E ?!<*1&*7$1\1;T9/2%2\3J>:#Z_(343"D1Z>=9$6]))#GJMHY
M2FKH:1&)T(6FU;F41"U$;#77ZZJBD9:0KY.TVPB!P+(AM"ZIK V[CUR$ ZI-
M1FDAF=C'/M 0@  08[)H*!0*';4E9II,ILK0A ]0)9#EP*D^0E+&/I0QD(/_
M+ < 8E@G^2;SDS%$8Q^9"( F]H$# ]!&6;*<30".>+@CCE0?:4!B6C*!!N^$
M80QMD>ED_ZD^'*@GAR@Y)<%6$]M],*)0&0G #8CQC-4V1QGKS&T T*"/W +
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M9 O*B"@[^RS:86X4LV*8Q#Z^&8UAYW:U;PAW+O?M \)+UCO0,&9'Z3$)>./
MV_I(IC]!/4QZ@)2R21I&2:6]3@ O(Q,;14,T^"E:'T1#\RK5?*873$Q<$GZU
MC*#P05D[T2RN5M(X6 8Q("QNS)[;TX@G1A@R 8J94&\A  A#/439;P.D-P
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M2Q,8@<-N(+U^ !J&P1/18/P 8 Q.$=,60E%L0 5D(+UN0 4P3378#[X&;[
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M*0)3V9J+O RO+?V+G?2O+35+LF")OYI+#!Q@P)9!#RFLU,*-F')K#/8AE]"
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MZGS4.J"L3F++0<W4XK:=!'*PH*7)9$$]L[9C8:9^I6R<WAQ%RS>V2'\?3$W
MLA/!JF#P,ENYRT,[=1JQY:^ )YRA!GL3_S>/W"^"+?+4X[2J5K<E!T\,7559
M:14JKK'MAB:\57!"!4"?!(Y ' G67<9R@Q*A\4UB0)\,@!+%)@+%<Y3%B$;>
MXI:6G2@J''1:6+L2 '_A1 !ZVHPQ4U+" VWI>.TC6;;@TB",Q,>/\ D 3+3#
M&]:$S6E=NX%S'BJXH &KG>J1SSN[U\ZR1 0!33Q37R9J1CHU#%VMH]EDY20#
MLC3%0, <:%:6.1GRE 0 @EH1=S[YG?T]RE,&H-]S,D4T\R*J6:#"SF76VQ,H
MG?(Y16+CL)33W\]\!7+ B>.S!)I@!.+GK<[Q;7WZ=QJI9:<X%?S7OU0) ,;=
M%YG/6I%,,O,\+?_>,&])'1L*K4B2 D4I00.J(K_8R,*XJ*L!9?I=MX2WHT.&
M2$)LR2A9[(11>()$HV?3I>U2B4RKYBF6!3Z;]+85%+50MK$0R?%K[;@>_"'+
MD^%Y((4%RMR[],1$OI*8X(I4X8\HEZ(]:XB[T-28H]CY0DAL".M^W-FWN-@G
MO;I/C*3VU+P)36X8 V[_M-HL!L:(O^51JD=3_!&!#2?!:Y[@\C!88&(]B]-:
M ?%^;2<J$FL'N*TA%'R+VK7#Q0TXN^$A M&:5%,2F(%:-64&19E@9P7RSUT<
M'&*A J_5041UP$-C^\B"/#].UGHDPU*85!9"G?RI4:GY(@Q0"X "$ZS_J4HE
MMHW+9)8 4)'9G,V(E7[R/N&4A)/SS15P^1?6)NVVS//AW/MXXJNO/(>%+W1N
M0[3E+IB=!2'=.O:=Q359@X?.<R_,R_.NW=>8",?34MMPH?N70P[V[6MK2VK]
M#JKJIF)F41@^0+=-H]N9Y(=L/T10HDB3&;LAZ8*)FTX 5NM@XT!5PDTC%,N/
MU9FK.DVJWEG6Q4-C-V[BZIM9,\G>#.W%K214/ EZ-[X%?)?__+F%1&;L$AO.
MK;?\3BUT@1U\_*Q9S:H%15XUG-3[)G>#$C,GFZG5ANL(DO>X)09ZY AF&QND
ME)F9KS R^G[I!T#+H$20O>KWK_+-]:;@J5 N_^P[6HZ=.ADH17BM"XJ[]/P6
M'5&W0\;C"%Q<]O45BF=7Q3$THO5:ZI4[AR0KB<Z,B$6:X0HG]P"H2?![SQOG
M!)\W!C"^5$:"7MTFE)F,FL]]?J.@\UA06I91+6B\B'?TJOPWZ.WV3&;"_%*:
M!+W'#/_W64X9U>P<E5%]FO#/RQ7>E+_;C>.-:8YO1>$G"^7VEWRL54 5<U@N
M=H $=3B_46D@X4+M87D.X!18IBY;PA?9@@"VA0!B42 MLX$]X0  9WD'V(!<
M\1_!5X*DH5OUUQ(MMS?GQWWZIX+^UVWT GAX]'7>52+F!G@GI23@UQ+M5QSB
MMQ+/EX*HI'(MD7O'=/\>+M2$(W@>!Y@3@1(;?!-E/O& .. 19_$3F_,M&:$N
M"3=/#7<6-[ "E^5V&P&%S\*!(:%;PB> 1.A%4K$2P@=^]<=\S,<;*M!AJ-1[
M.:%\U.1]80 AJK,0/J Z8C"(![$0BJ@4C*A$CR@1$=$F!\$C@[@%B)A3?Q$&
M/3"( C&(:3*(8L C[9(4H&B*8>")YO(A C&)JI.*DU@G;7**A9@C</**GB@1
MH#B*B&@N1R&*#T(0Y](8"I&*R+:*J2.*C.&(O?B(!+$8RUB)SRB-9S"*TQ@&
M:+ 0BX$&.# & \&-H^B-/C 08P". S&.W[B-"6&-["@&Z#B-[!@&.:"-IIC_
M4X/8 Q)!3[ XB8)AC$<A+K2XCM!H(:.8 ^WXC.R(!J-HC>4XC0^RC\CF(353
M%+D(,XU(C\+XB (1,QM9B=HHC=(H$3>CB*W(+@FAD 2!CFFPD&*@D*/HDBRY
MD"A9D-PXC>^(CNY8%*,8!CX@C*GCB*<H&.:2CZ\((:*(;*#HD<7HBK:H$#>P
M#U 9E5(YE50)E?50E5%YE5BY#UHYE5TIE5?YE5@IEF"YE699E61YEEFIEFS9
MEF[)EFFY#_H0EV<9E_I0E=%PEV>IEWH9E7TIEW#YEH)9EFIYEW0)F%)YE]&
ME7.)EH$YEE1YF([IE6M9F9:)E8NY#WFIF5"9F9SY+YF;295_N96-R964V9:2
M:96#N9JLV9JN^9JP&9NR.9NT69NV>9NXF9NZN9N\V9N^2?F;P!F<PCF<Q%F<
MQGF<R)F<RKF<S-F<SOF<T!F=TCF=U%F=UGF=V)F=VKF=W-F=WOF=X!F>XCF>
3Y%F>YGF>Z)F>ZKF>[!F; 0$ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image01.jpg
<TEXT>
begin 644 image01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MQ?LXI"NF:=)< 'AY7V _@ :X'Q5XEN?$NKO<3,RP*2L$.>$7_$]Z7PSX5O\
MQ1>-%9;8XH\&69_NI[>Y]JX)8B<I<M,^QP^38:A1]KC'ZZV2.OC^,=P''G:1
M$5[[9B#_ "KK/#_Q!T;7I5MP[6ETW"Q3X&X^S=#^AKA=9^%.HZ=I[W5E=I?&
M-=SQ",HV.^.3FN#!*MD'!%3[6K3?O&JRW+<;3;P^GFK_ (IGT_17$_#;Q3)K
MFEO97S[[RT ^<GF1.Q/N.GY5VU=\)*<>9'R&)P\\-5=*>Z"BBBJ.<Y[QOXMA
M\$^%Y=:N+62[CBD1#%&P4G<<9R:\R'[3&E9Y\/7G_?\ 3_"NJ^.J[OA%J?\
MLR0G_P B+7R70,^Q_&?Q/T#P38Q2:A*UQ=SQAX;.#!=@>A/91[G\,UY7-^TS
M?&<FW\-VXBSP'N6+$?4+7FNA^&/%/Q)UB9["*2]F4+YUS,^U(P!A06/L, #T
MZ5)XO^&?B7P3;QW.M6B&UD;8+B"3>@;T/<'ZB@#Z \"_&[0_&%['IUY"^E:C
M)Q''*X:.4^BOQS[$"O2Z^"4=HY%>-BCJ0593@@^M?9?PS\2R>+/A[INIW+;K
MG88;@^LB':3^. ?QH$>-_M+?\C9H_P#UY'_T,UY7X7_Y&[1_^OZ'_P!&"O5/
MVEO^1LT?_KR/_H9KRKPQ_P C=H__ %_0?^C%H&?<E%%(S!5+,0 !DD]J!' _
M&Z^2R^$NJJY&;@QPH/4EP?Y U\C5ZW\=?B';^)]6@T31IA-I^GN6DF0Y6:;I
MQZA1D9[Y->56MK->WD-K:QM+/,XCC11RS$X H&?3W[/-D;;X9-,PQ]JO9)![
M@!5_]EKSG]H__DH%C_V#U_\ 0WKZ!\(:"GACP?IFC)@FT@"N1_$YY8_BQ-?/
MW[1__)0+'_L'K_Z&] ' >!/^2A>'_P#L)6__ *,6OMFOB;P)_P E"\/_ /82
MM_\ T8M?;- 'RK^T!_R56;_KTA_D:P/A5_R57P__ -?8_D:W_P!H#_DJLW_7
MI#_(U@?"K_DJOA__ *^Q_(T ?9->?_''_DC^K_[T'_HY*] KS_XX_P#)']7_
M -Z#_P!')0(^1Z^O/@K_ ,DBT;_=D_\ 1C5\AU]>?!7_ ))%HW^[)_Z,:@9V
M.K?\@6]_Z]Y/_037PD>M?=^I(9-)NT7DM X'_?)KX18$,0>"#S0!]#?LS?\
M('U__KO#_P"@M7N->"_LS7T037[ L!*3#,J^J_,#^I'YU[RS!5+,0% R2>U
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MW1_^O$_^C#7CMC=R:?J-M>0A3);RK*@8<$J01G\J^J?B;\)?^%AZG:7JZO\
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MK[(+DH?.";]NUPW3(],4"/B>OKSX*_\ )(M&_P!V3_T8U<#_ ,,R)_T-#?\
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M[\>&\5^%[G1=-T<V<=V LTTTV\[00<  #KCK7D,44D\R10HTDDC!411DL3T
M%>S6W[-6N/(/M>N:?$F>3&CN?R('\Z]-\#?!KP]X+N4OR7U+4D^Y<7  $9]4
M3H#[G)H&=!X T*7PSX!TC2;@8GMX 91Z.Q+,/P+$5\M_%O\ Y*QK_P#U\_\
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MKVE_VYX=O]+,OD_;+=X?,V[MFX8SCOUH$?"]?3O[./\ R3B\_P"PG)_Z+CK
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M+\V!'$T<)D!'#E9'P3],#\J -/5/CMXKT 0ZIK_PYO+'0)G 6X>8^8 >F1C
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MG'S(H 920.N"K=1G!'(K)^)-Q\0OBIX&GCL/"%UHVF6S),UO<G?=7S[@ J(
M"%7)8^N*^A:* /-[K1]2F_9M.D)8W']I'0!!]D,9\SS/+ V[>N<]JJ?"BP\0
M^%?@'% -&E.N6RW+PZ?<?NV=S(Q0'., Y'X5ZG10!XGJ7Q3\<ZIHMUHT/PLU
M2/5;B!H2TA)MU+#!8DJ 1STS^-=;\&/ =Y\/OA_'INJR*U]<3M<SHC;EC9@
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, ]Z]#HH **** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
